Production, regulation and role of nitric oxide in glial cells

V. A. M. Vincent, F. J. H. Tilders and A-M. Van Dam[CA]

Research Institute Neurosciences Free University, Medical Faculty, Department of Pharmacology, Amsterdam, The Netherlands

[CA]Corresponding Author
Tel: (+31) 20 4448095
Email: AMW.van_Dam.pharm@med.vu.ul

Introduction

The central nervous system (CNS) consists of two major cell types, neurones and glial cells. Neuronal communication with other neurones or glial cells is effected mainly through neuro-transmitters and peptides, while glial cells appear to use an abundant range of factors for the communication with either neurones or other glial cells. The communication between neurones can span large distances in the body, while glial cell communication is mainly local or paracrine. During the past decade it has become clear that the glial cells named after glue (= glia) have more functions besides acting as a "nerve-glue" to form the brain.[1,2] The glial cells appeared to be essential for neuronal protection, survival and outgrowth during development and for the neuronal degeneration and regeneration under pathological conditions. In this review we summarize glial cell functions and focus on the role, production and regulation of nitric oxide (NO), a molecule which has been shown to be involved in various neuroimmune processes.

Glial Cells

Glial cells can be divided into microglial cells and macroglial cells, the latter of which are subdivided in astroglial cells and oligodendrocytes. The oligodendrocytes are known for their myelin production that wraps the axons in the white matter of the brain, and are affected in diseases like multiple sclerosis (MS). Glial cell activation has been indicated in many neuropathological diseases like Alzheimer's disease,[3-7] Parkinson's disease,[5] multiple sclerosis,[8] acquired immune deficiency syndrome (AIDS) dementia complex (ADC)[9-11] and other disorders.

Microglial cells

Microglial cells, formerly named Hortegaglia or Mesoglia, have been described in detail for the first time in 1932 by Del Rio-Hortega[12] considered as the father of microglia. Microglial cells are ubiquitously distributed in the CNS, show heterogeneous morphology and comprise up to 20% of the total glial cell population in the brain.[13] It was Del Rio-Hortega who proposed that microglial cells occur in two morphologically distinct forms, the ameboid or macrophage-like form representing as active microglial cells seen in developing brain and at sites of injury. These cells convert into the highly branched ramified microglial cells[14-17] viewed as quiescent cells in the mature CNS[18] which eventually can transform into active macrophages (reactive microglial cells) (Fig. 1).[19,20] Del Rio-Hortega suggested that microglial cells served as macrophages or phagocytic cells, which has found substantial support.[21-23]

The name mesoglia was derived from their proposed mesodermal origin. Indeed more recent and elaborative studies support a bone-marrow origin[17,24] from the usual macrophage precursor. Blood monocytes or monocyte precursors invade the brain during development.[25,26] In studies using chimeric rats, support was found for the bone marrow origin hypothesis[27,28] but in other rat chimera experiments the contrary was found.[29,30] The prevailing concept is however that blood monocytes are the precursors of ameboid microglial cells. There is apparently no need

FIG. 1. Microglial cell activation cascade. Schematic drawing illustrating the transition of microglial cells from ramified microglial cells to the ameboid microglial cell, adapted from Ref. 371.

for the influx of a large number of monocytes into the brain parenchyma under normal conditions, since microglial cells have an extreme long life and have a low turnover rate.[31,32] Their numbers can be augmented by local proliferation[19,33–36] or by immigration of blood monocytes.[37] Under pathological conditions increased monocyte infiltration into the brain parenchyma is found[8,38,39] and the influx is suggested to be mediated by the microglial cell derived chemokine MCP-1[40] or adhesion molecules.

Microglial cell functions
The microglial cells serve as immunoregulatory cells, and are essential for resistance to inter- and intracellular pathogens. The microglial cells are present in a resting or a ramified form (Fig. 2) and are very important in immunosurveillance. After activation of the resting cells the microglial cells exhibit a highly potent phagocytic activity of foreign organisms and material, phagocytosis of injured or necrotic tissue, antimicrobial immunity, elimination of tumour cells and regulate inflammatory responses.[41] Microglial cells have been reported to possess Fc receptors,[18,42] CD4 antigen[43] and major histocompatibility complex (MHC) class I and II antigens[41,44–46] and thus are antigen presenting cells. Interferon-γ and interleukin-4 (IL-4) up-regulate MHC class II expression and induce microglial cell proliferation.[47] In addition, microglial cells show chemotaxic activity, like monocytes and macrophages, to several immunological factors such as complement factor C5a and to transforming growth factor β (TGFβ) suggesting that these cells can move to sites of injury and thereby participate in an inflammatory response.[12,42,48,49] These observations have led to a redefinition of the brain as immune privileged site a concept based on

lack of inflammatory responses through the absence of T and B cells.

Microglial cells share many functional characteristics with cells of the monocytic lineage. Interleukin-1 (IL)-1 production by microglial cells has been demonstrated for the first time by Giulian,[50] and later by many others[41,51–54] and IL-1 is found to be present in injured brain tissue.[50,55] Other cytokines produced by microglial cells are TNF-α,[54,56,57] IL-6[57–59] and TGFβ[60–62] and they produce prostanoids such as prostaglandin E_2, (PGE_2), PGD_2, thromboxane[63,64] and leukotrienes, LTB_4, LTC_4 and 5-HETE.[65] IL-5 was found to be produced by microglial cells *in vitro* which may be involved in the interaction between glial cells and immune cells in the brain.[66] IL-10 and TGFβ both immunosuppressive and anti-inflammatory cytokines, have been demonstrated to be produced by human microglial cells and down-regulate microglial cell functions.[60,67–71] These properties confirm that microglial cells can initiate and regulate immune and inflammatory responses within the brain.

Astroglial cells

Astrocytes, oligodendrocytes and neurons are of ectodermal origin, and derive from the neuroepitelium of the primitive neural tube. Astroglial cells, unlike neurones, retain the ability to divide throughout life.[72] The multipotential stem cell develops into the bipotential progenitor cell and finally the glial lineage-restricted progenitor cell which can differentiate into the oligodendrocyte, the astrocyte type 1 and type 2.[73–76] The astrocytes outnumber neurones 10:1 in mammalian brain, and as their name imply, they have a star-shaped morphology. The astrocytes can be identified by using specific markers such as glial fibrillary acidic protein (GFAP), and glutamine synthase (GS), that are specific for both types of astroglial cells.[77–81]

Each cell forms processes that contact the blood vessels, where they form the so-called end-feet or sucker processes which also forms part of the blood–brain barrier (BBB) together with endothelial cells and the lamina basalis.[72] Astrocytes in the white matter are referred to as fibrous astrocytes, with numerous fibrils within their cytoplasm. In the grey matter, the astrocytes generally contain few fibrils and are called protoplasmic astrocytes. Interestingly, *in vitro* also two types of astrocytes can be identified, type 1 and type 2 astrocytes which are thought to be *in vitro* analogous of the protoplasmic and fibrous astrocytes respectively[82] (Fig. 2).

Astroglial cell functions
Initially the function of astroglial cells was thought to be a structural support within the CNS, with their processes having junctions with other astroglial cells, endothelial cells and neurones. In addi-

FIG. 2. Microglial cells and astroglial cells in rat brain *in vivo* and *in vitro* stained for GSA-I-B4-isolectin and GFAP respectively. (**A**) GFAP staining of astroglial cells in rat brain; (**B**) GSA-I-B4-isolectin staining ramified microglial cells in a rat brain; (**C**) GFAP *in vitro* in a purified astroglial cell culture; (**D**) GSA-I-B4-isolectin *in vitro* in a purified ameboid microglial cell culture. A, B, bar = 66 mm; C,D, bar = 25 mm.

tion in repair mechanisms the astroglial cells fill open spaces by proliferating and thereby forming a glial scar.[83–86]

It is now known that astroglial cells are very important cells in the outgrowth and survival of neurones during development and in neuropathology. Astroglial cells produce nerve growth factor (NGF)[87] *in vitro* and *in vivo* and the production of NGF is increased by IL-1,[88–92] TNFα,[93] IL-4 and IL-5.[94] Other neurotrophic factors produced by astroglial cells are ciliary neurotrophic factor (CNTF), brain-derived neurotrophic factors (BDNF) and fibroblast growth factor (FGF).[95,96]

Astrocytes produce cytokines like IL-1,[41,97–100] IL-6,[101] IL-3,[102] TGFβ[60,62,103–105] and IL-15[106] and factors like prostaglandin E$_2$ (PGE$_2$),[97,99,107,108] granulocyte-macrophage colony-stimulating factor (GM-CSF)[109,110] and microglial mitogens (MM).[111] TNFα is also produced by astroglial cells *in vitro* after lipopolysaccharide (components of Gram-negative bacterial outer membranes; LPS)[56,112] and IL-1β stimulation[59,106] or mycoplasma infection.[108]

Astrocytes can be induced to express MHC I and II class molecules *in vitro* and are able to present antigen[113,114] and thus are important immune cells in

the brain. However, in contrast to microglial cells they do not express significant levels of MHC class II molecules[115] *in vivo*.

Glia–glia interactions

Recent studies have shown various interactions between microglial cells and astroglial cells. IL-1 produced by microglial cells has been shown to stimulate astroglial cell proliferation *in vitro*.[116–119] Intracerebral injections of IL-1 or local production of IL-1 by microglial cells elicit astrogliosis which may result in scar formation[120,121] and thereby have a negative effect on axonal outgrowth and remyelination. In addition the microglial cells influence the production of NGF by astroglial cells, which is enhanced after IL-1 and IL-5 both produced by microglial cells.[66,94,122]

On the other hand, astroglial cells influence microglial cell functions. Interleukin-3 (IL-3) is mitogenic to microglial cells and has been suggested to be produced by astrocytes.[102,123] Mitotic activity of microglial cells can additionally be elevated by colony stimulating factor-1 (CSF-1), which production is increased by IL-1, TNFα,[124] granulocyte-macrophage

colony-stimulating factor (GM-CSF)[41,109,110,122,125–127] or microglial mitogen (MM).[111]

The microglial cells undergo morphological changes in response to factors released by or through cell–cell contact with astrocytes. These factors derived from astrocytes, induce microglial cells to become the ramified, functionally resting cells *in vitro*, while inflammatory mediators like interferon γ (IFNγ) and LPS induce microglial cells to become ameboid.[128,129] Also, blood monocytes and spleen macrophages differentiate into ramified microglial cells when cultured onto an astroglial cell monolayer.[130,131] This illustrates the capacity of astroglial cells to transform cells from monocytic origin into cells with microglial cell morphology.

In addition, astroglial cells have been shown to functionally regulate microglial cell activity. The endotoxin induced synthesis of iNOS and release of NO but not the production of IL-1β by microglial cells is inhibited in the presence of astroglial cells *in vitro*.[51]

Apparently both glial cells communicate through the production of various factors including cytokines and growth factors. In this way the glial cells appear to tightly regulate each others morphology, activity and secretion of products.

Glia–neurone interactions

The presence of glia-derived cytokines in the CNS and the function of these cytokines *in vitro* suggest that they are important for normal brain development and homeostasis.[132,133] However, excessive expression of these cytokines may be a factor in abnormal glial functions leading to neuropathological events.

In general astrocytes have been found to express neurotrophic factors such as ciliary neurotrophic factor (CNTF), neurotrophin-3, fibroblast growth factor (FGF) and NGF near the site of injury.[134,135] *In vitro* experiments show that astrocytes protect dopaminergic neurons against H_2O_2 toxicity[136] through actions of glutatione. Interestingly, survival of these dopaminergic neurones *in vitro* is enhanced by the presence of glial cells derived from striatal astroglia: the target-derived astroglial cells, illustrating astroglial cell heterogeneity.[137,138] The survival of dopaminergic neurones is promoted by glial cell-lined derived neurotrophic factor (GDNF) *in vivo*.[139] *In vitro* cocultures of neurones and astrocytes induced an increased cell survival and neurite outgrowth[140–142] and axons might trigger glial differentiation.[143] The ability of astrocytes to augment neuronal survival was increased after treatment of the astrocytes with macrophage conditioned medium[144] indicating that factors produced by macrophages induce the production of neurotrophic factors.

Neurones are less sensitive to oxygen or glucose deprivation or treatment with glutamate when co-cultured with astrocytes.[145] In addition astrocytes increase neuronal survival under pathological conditions since they have an energy reserve stored as glycogen which becomes available for neurones under conditions of energy substrate limitations.[146] Astroglial cells are important in the metabolism of glutamate and GABA and other neurotransmitters,[147] and maintain the microenvironment by regulating the ionic composition of the extracellular space around the neurones.[148]

Neurotrophic effects i.e. neuronal survival and neurite extension have also been reported by microglial cell conditioned medium[149] and more specifically by the production of NGF[150] and thrombospondin.[151,152] In addition secretion of IL-6, IL-1, FGF, TGFβ, TNFα by microglial cells and astroglial cells may stimulate nerve growth factor production by astroglial cells for the regeneration of neurones.[93,134,153–158] These factors also directly improve the survival of neurones and/or have synergistic effects with NGF.[159,160]

While in general factors released by astroglial cells actually increase the survival of neurones,[161] microglial cells in contrast, can directly participate in neuronal cell death through the release of neurotoxins.[162] Microglial cells have been reported in the presence of degenerating neurones in various regions in the brain.[18,163–165] In these regions the microglial cells clearly contribute to the removal of pycnotic cell bodies. Prior to this scavenger role, the active participation of microglial cells in neurite amputation has been shown on electron microscopic pictures of microglial cells engulfing axon processes which display no obvious signs of degeneration.[166] It is therefore thought that interactions between neurones and microglial cells may not be restricted to cell debris scavenging but microglial cells may also induce neuronal cell death.

In vitro studies have demonstrated the production of many different neurotoxins by microglial cells. Activated microglial cells release several cytotoxic compounds i.e. reactive oxygen intermediates,[167,168] NO, proteases[51,169–172] and inflammatory cytokines i.e. IL-1, TNFγ or TNFα,[50,56,119,127,157,173,174] that play a role in neuronal damage in the CNS. Finally microglial cells produce large amounts of glutamate and aspartate *in vitro*.[175] The release of these excitatory amino acids points to a further role of microglial cells in NMDA receptor-mediated neuronal injury.[175] In addition, cultured microglial cell release large amounts of H_2O_2, which leads to neuronal cell death in neurone–microglial cell cocultures.[172,176,177]

Taken together, activated microglial cells display a broad repertoire of cytotoxic functions which could be involved in tissue damage during CNS injury. In addition, microglial cells activate astroglial cells in a way that benefits regeneration. Further, the effect of neurotoxic factors released by microglial cells can be

attenuated by proteins released from astroglial cells.[178,179] This illustrates the fascinating and delicate interactions that exist between glial cells and neurones, which are crucial in maintaining neural functioning and integrity. These studies have contributed towards a concept which considers reactive microglial cells as an opposing force to neurotrophic astroglia, the two glial cell populations rivaling in regulating survival of neurones.[180]

Nitric Oxide in the CNS

Various cell types in the CNS, i.e. neurones, endothelial cells, microglial cells and astroglial cells produce NO. Different isoforms of the nitric oxide synthase (NOS) are responsible for the production of NO by these cell types. NO in the brain is multipotent and is responsible for blood flow regulation, may act as a neurotransmitter or as a neurotoxic agent, depending on the cellular source, amount and production site.

Isoforms of nitric oxide synthase

NO, a free radical gas, was found to be responsible for the vasodilatation in arteries and at first named endothelium derived relaxing factor (EDRF).[181] Later the source of NO was elucidated revealing the enzymatically conversion of L-arginine to L-citrulline by NO synthase whereby NO is produced (Fig. 3).[182] Three isoforms of NOS, encoded by different genes[183] have been characterized, isolated and cloned to further study the physiologic and/or pathologic functions of NO.[184] All three isoforms, endothelial (eNOS, ecNOS or type III), constitutive (cNOS, nNOS, bNOS or type 1) found in astroglial cells and neurones and inducible (iNOS, mNOS, macNOS or type II), NOS are found in the CNS and play a role in certain physiological or pathological functions of the CNS (see following section).[185] Constitutive NOS is constitutively expressed in neurones, is Ca^{2+} and calmodulin dependent, and mediates the production of only small amounts of NO after stimulation. This neuron derived NO is very rapidly produced and released since cNOS is constitutively expressed and does not require mRNA synthesis, acts as a neurotransmitter with properties that differ from other neurotransmitters: (a) it is not stored in vesicles, (b) there are no specific release or uptake mechanisms and (c) its transmission is not synaptic. NO diffuses into the target cell and directly regulates enzymes systems, such as activation of guanylate cyclase, resulting in increased cGMP levels.[186,187] NO has a half life of a few seconds in contrast to the milliseconds of the neurotransmitters in classical synapses.[188,189] It is important in neurotransmission, and NO is considered a candidate for a memory-related process named long-term-potentiation (LTP).[190,191] Indeed, inhibitors of NOS can


FIG. 3. Biosynthesis of NO through the so-called L-arginine-NO pathway, adapted from Ref. 372.

block LTP.[192,193] In areas such as the cerebral cortex, hippocampus, cerebellum and corpus striatum, cNOS expressing neurones compose 1–2% of all neuronal cells.[194] Activation of cNOS in astroglial cells was observed after challenge with calcium ionophores, bradykinin or glutamate.[185]

Endothelial NOS (eNOS) produced by endothelial cells is a constitutive Ca^{2+}-dependent enzyme that is essential for the control of vascular tone. NO transduces a signal from the endothelial cell to the vascular smooth muscle eventually leading to cGMP production and vasodilation. In the brain, eNOS-derived NO regulates cerebrovascular blood flow.[195]

Inducible NOS (iNOS) is a Ca^{2+} and calmodulin independent enzyme. It requires gene transcription, is slowly produced and is activated only under pathological situations where microglial cells and macrophages exert cytotoxic effects in response to cytokines.[196] The generation of NO by iNOS is long-lasting, in contrast to the cNOS and eNOS isoforms where NO is generated in short bursts.[197,198] The mechanism of iNOS induction involves transcription of mRNA and novel protein synthesis and it takes several hours before NO is generated after the initiating signal.[199] It induces a 100-fold higher local concentrations of NO than eNOS or cNOS and act as a antimicrobial defence mechanism of the immune system. iNOS is not expressed in normal brains but expression can be induced in astroglial and microglial cells through viral infection or trauma.[200,201] It is mainly expressed under inflammatory conditions, and after transient ischaemic periods.[202–205]

Nitric oxide in neuropathology

NO can be neurotoxic under different circumstances. The NO mediated neuronal cell death can be induced by overexpression of cNOS in neurones and astroglial cells or iNOS induction in glial cells, both pathways will be further discussed below (see Fig. 4).

cNOS induced NO mediated neurotoxicity
Glutamate binding to its NMDA receptor induces NO production by cNOS activation. Derangements of

Nitric Oxide Mediated Neurotoxicity

FIG. 4. NO as neurotoxin. Excessive NO is formed on sustained glutamate stimulation of NMDA receptors by cNOS in neurones or by activation of iNOS or cNOS in glial cells. NO freely diffuses to adjacent target neurones where it combines with the O_2^- to yield the peroxynitrite, $ONOO^-$, which is an extremely potent oxidant. Although NO can function as a toxin directly, the peroxynitrite pathway may be the major pathway of cell death, adapted from Ref. 303.

glutamate neurotransmission leading to neurotoxicity has been implicated in Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), epilepsy and stroke.[206,207] Glumate neurotoxicity is demonstrated to be mediated through NO production. After binding of glutamate with the NMDA subtype of glutamate receptors, Ca^{2+} enters the channel and binds to calmodulin, a cofactor for cNOS and stimulates NOS activity whereby NO is produced.[208] In addition, O_2^- is produced which results in the formation of $ONOO^-$ which subsequently leads to neuronal death.[209-211] Neurones obtained from cNOS null transgenic mice are markedly resistant to ischaemic conditions,[212] in which the primary mechanism of damage is mediated by activation of the NMDA receptor and subsequent formation of NO. This indicates that cNOS is capable of producing neurotoxic amounts of NO.[213]

iNOS induced NO mediated neurotoxicity
The iNOS-mediated release of NO by astrocytes and microglial cells in the brain may be important in antimicrobial or tumoricidal responses to inflammatory signals.[197] In acute CNS inflammatory conditions like rabies, herpes simplex, Borna, and lymphocytic choriomeningitis virus, iNOS is expressed[200,214-217] as well as in experimental pneumococcal meningitis and toxoplasmosis and in humans during encephalitis.[130,218-220] iNOS mediated NO is considered to mediate neuronal and oligodendrocyte degeneration under neuropathological conditions.[202,221,222] The role of iNOS in neuropathology in general is indirect, microglial cells and/or macrophages become activated either through direct infection with virus or other pathogens, or by local cytokine production and subsequently produce iNOS which eventually leads to damage. Excessive amounts of NO produced by glial cell are probably neurotoxic. iNOS-derived NO is one of the major sources of toxic free radicals in the brain, since its reaction with the superoxide anion (O_2^-) leads to the formation of peroxynitrite anion ($ONOO^-$) which is an extremely potent oxidizing agent.[223] Peroxynitrite generates DNA-single-strand breaks with subsequent activation of the DNA repair enzyme poly ADP ribosyltransferase (PARS).[224] Furthermore, NO and peroxynitrite have been shown to inhibit the mitochondrial respiratory chain and disrupt normal cellular iron homeostasis.[201,225-227] Peroxynitrite and/or NO can terminally damage neurones, leading to cell death.[228-232] Low levels of or sustained exposure to NO or peroxynitrite cause apoptosis, whereas sudden exposure to high concentrations of NO or peroxynitrite leads to necrosis.[233]

NO in Alzheimer's disease and MS
iNOS expression is found in Alzheimer's disease[234,235] and in experimentally infected brains of rats with various viral agents.[200] NO has been implicated in demyelination and destruction of oligodendrocytes and subsequent demyelination, the process found in MS[236] and in the primary animal model for MS, experimental allergic encephalomyelitis (EAE).[216,237] During EAE, iNOS mRNA is detectable before the onset of the clinical symptoms and the levels of protein correlate with the severity of the disease.[200] Further evidence supporting a role for iNOS in the pathogenesis of MS is the finding that human iNOS protein and mRNA is markedly elevated in the active lesions in brains of MS patients.[238,239] In MS lesions, macrophages appear to produce iNOS and are NADPH-diaphorase positive after histochemical staining.[240] In another study, NADPH-diaphorase activity in MS lesions was found in reactive astroglial cells[239] which was later shown to be cNOS.[240] The cellular source of iNOS mRNA expression in brains of patients with MS has been confirmed to be macrophages/microglial cells.[238] In EAE an increase was found in eNOS in blood vessels in the inflamed lesions and increase in iNOS in infiltrating inflammatory cells.[216,241] iNOS expression can be (further) induced by cytokines like TNFα, IFNγ and IL-1, that are all detected in brains of MS patients.[242-245]

NO in AIDS dementia complex
iNOS-mediated NO production has also been described to be involved in acquired immune deficiency syndrome (AIDS)-related neuropathology. iNOS protein and mRNA was found in the CNS of patients with AIDS dementia complex (ADC),[246,247] and is

expressed at higher levels than in brains of AIDS patients without neurological symptoms. The cell types expressing iNOS however, remain unknown. In these patients there is a clear correlation between the severity of the dementia and iNOS expression in the brain. In addition in brain tissue of simian immunodeficiency virus (SIV) infected monkeys iNOS mRNA was detected.[248] The microglial cells have been postulated to be involved in the pathogenesis of ADC because they are preferentially infected by the virus.[43,249–251] Neuropathological manifestations such as loss of cortical neurones, loss of synapses and neuronal apoptosis have therefore been suggested to be mediated indirectly by cytokines like TNFα[252,253] and IL-1[254–256] or by nitric oxide.[257–261] TNFα, IL-1 and iNOS have been demonstrated in brains of AIDS patients[247,256,262–265] as well as in ADC patients[259,266,267] (Vincent *et al.*, submitted). In cytomegalovirus (CMV) infected retinas from AIDS patients iNOS immunoreactivity and NADPH-diaphorase were found in (CMV)-infected cells identified as Müller cells and astrocytes.[268]

NO in parkinson's disease
In Parkinson's disease, which is primarily characterized by a loss of midbrain dopaminergic neurones, iNOS was present in glial cells[269] in the mesecephalon probably in activated macrophages.[269] In addition, NOS inhibitors attenuate malonate-induced degeneration by NMDA receptor activation of the nigrostriatal pathway in rats[270] suggesting a role for NO in neurodegeneration. The inhibition of tyrosine hydroxylase resulting in reduced dopamine synthesis is triggered by peroxynitrite, a reaction product of NO.

NO in brain activation
During ischaemic brain damage eNOS is induced in endothelial cells which then has beneficial effects by enhancing the vasodilation, further increasing blood flow in the peri-infarct area.[272,273] In addition iNOS is induced leading to NO production, which leads to neuronal death after cerebral ischaemia.[274] During postnatal brain development of rats, large numbers of NADPH-diaphorase positive neurones and NADPH-diaphorase positive cells with macrophage morphology were observed. The latter are possibly involved in developmental shaping of the brain, which includes cell death and fagocytosis of cellular debris.[275] High levels of NADPH-diaphorase were found in evenly distributed astroglial cells in areas surrounding a mechanical lesion in the brain. Within the lesion the NADPH-diaphorase positive cells most probably were macrophages.[276]

Thus, although iNOS and NADPH-diaphorase activity can be induced in astrocytes and microglial cells through viral infection or trauma most of the studies have revealed iNOS immunoreactivity and iNOS

mRNA in the brain in infiltrating macrophages or microglial cells.[210] In general, exposure of brain cells to signals, such as microbial products, viruses, glutamate or yet unknown signals in diseases like MS, Alzheimer's and Parkinson's disease leads to the secretion of inflammatory cytokines that induce either *de novo* synthesis of iNOS by glial cells or cNOS in astroglial cells or neurons as has been demonstrated in *in vitro* studies. This NO may be neurotoxic and may subsequently lead to neuropathology.

Production of iNOS *in vitro*

To answer some more fundamental questions regarding iNOS production and regulation *in vitro* studies are widely used. Sources, induction mechanism and intervention of iNOS production are studied in detail in various glial cell cultures. In addition, a model has been developed that allows studies of the possible neurotoxic effects of glial NO, on cultured neurons. These *in vitro* studies have led to new insights in the functions of glial cells in normal brain and in neuropathology.

Several techniques have been described for isolation of rat murine or human brain microglial cells, astroglial cells and maintenance of these cells *in vitro*.[118,240,277–282] The microglial cells and astroglial cells are isolated from mixed glial cultures in most instances or from disrupted adult or neonatal tissue.[53,127,171,279,283–285] In tissue culture, the ameboid and ramified microglial cell can be identified, most probably corresponding to its morphological diversity in the adult brain.[286] The astroglial cell cultures can be contaminated with microglial cells, since the purification of astroglial cells is a rather delicate technique and microglial cells remain a significant contaminant.[56,161,287] Many studies showing production of, for example, cytokines like IL-1 or TNFα by astroglial cells *in vitro* have to be interpreted with care. *In vitro* studies also provide a very useful technique to study both the functions of glial cells and of neurones as well as the interactions between these cell types. Therefore techniques for selective isolation, co-culturing, labeling and stimulation of microglial cells and astroglial cells allow investigators to study some fundamental questions in neuro-immunology.

Glial cell-derived iNOS
iNOS expression by glial cells has been studied in *in vitro* systems of highly purified microglial cell and astroglial cell cultures and in mixed cultures containing both cell types from human or rodent brain. Following incubations with various stimuli, both microglial and astroglial cells have been demonstrated to produce nitrate, one of the end-products of nitric oxide oxidation.[203]

iNOS has been identified in rodent astrocytes and microglial cells in response to IL-1β, LPS or Gram-positive bacterial products.[185,259,288,289] IFNγ induces NO in microglial cells and macrophages but not in astroglial cells,[203,221,290–292] while synergism of IFNγ and IL-1β or TNFα induce significant levels of nitrite in rodent and human astroglial cells.[203,239,250,293,294] LPS induction of iNOS required CD14 expression on glial cells.[295] As yet it is not clear whether cytokines activate gene expression via one or multiple pathways. Experiments with phorbol esters, which induce iNOS, suggest that protein kinase C may be involved in the induction process in microglial cells and astrocytes.[296]

Agents like IFNγ and LPS are more effective inducers of iNOS in rodent than in human microglial cells,[198,250,288,297] which therefore appears to be species-dependent as described for NO production by retinal pigment epithelial cells.[298] Recently, some studies did however reveal NO and iNOS mRNA production in human ramified microglial cells upon LPS or TNFα stimulation.[267,299]

HIV or the HIV type I coat proteins gp120 or gp41 induce iNOS in cultured microglial cells, monocytes or macrophages.[9,246,257,258,266] In human fetal glial cells, comparable amounts of NO were induced by gp120, gp41 and the proinflammatory cytokines IFNγ and IL-1β.[9] HIV-infected brain mononuclear macrophage secrete NO and O_2^-,[266] especially after immune activation and TNFα further increases NO production. In MS and EAE, macrophages isolated from lesion areas produced significant amounts of nitrite and were shown to be iNOS positive without any further stimulation.[240,300]

β-amyloid, the major component of the senile plaques in Alzheimer's disease, causes a significant increase in NO by microglial cells and not in astroglial cells. The NO production induced by the β-amyloid was increased by IFNγ[301,302] or phorbol-myristate-acetate (PMA) challenge.[168]

Studies that have attempted to compare rat microglial cell and astrocyte NO production have concluded that microglial cells produce more NO on a per cell basis than astrocytes.[202,222,290] This has led to the suggestion that activated microglial cells rather than astrocytes are the principal source of reactive nitrogen intermediates in the CNS, and that the NO produced by astroglial cells might be beneficial, whereas microglial-derived NO might be involved in neurotoxicity.[185]

Nitric oxide mediated neurotoxicity in vitro
In vitro co-cultures of glial cells with neurones have proven to be a valuable tool in the identification of NO as a neurotoxin and the cellular sources of NO. Exogenous NO generated from NO donors have been shown to kill neurones *in vitro*.[224] Cytokine-activated murine microglial cells and astroglial cells apparently generate substantial amounts of NO that kill neurones *in vitro*,[202,222,259,288,303,304] since inhibition of endogenously formed NO by specific NOS inhibitors blocks this microglia- or astrocyte-mediated neurotoxicity.[202,260,305] For example, factors like LPS, gp41 and β-amyloid can indirectly kill neurones in mixed cultures with glial cells, which is abrogated by NOS-inhibitors.[246,301] LPS or cytokine activated glial cells stimulate the production of neurotoxins, e.g. NO, because LPS and cytokines do not directly influence the viability of purified neurones.[307] These studies clearly illustrate the indirect mechanism by which neurones are thought to be killed.[306]

The glial cells produce large amounts of NO by iNOS activity which can form peroxynitrite which is toxic to neurones as previously described. In addition, glutamate neurotoxicity is also mediated by NO in primary neuronal cultures.[303] Peroxynitrite, NO and NMDA can damage neurones *in vitro* leading to necrotic or apoptotic cell death pending on the concentration and duration of the exposure.[229] In addition, oligodendrocytes are also being killed by an NO dependent mechanism by ameboid microglial cells *in vitro*, suggesting that iNOS expression by invading and intrinsic brain cells play a role in lesion formation in multiple sclerosis.[221]

Although glial cells produce various neurotoxins i.e. TNFα, glutamate and PAF, production of NO appears to play a key role in different neurotoxic pathways since inhibition of iNOS spares the neurones.[260,305,308] These *in vitro* findings suggest an important role for glial iNOS derived NO in the pathophysiology of CNS diseases.

Regulation of NO Production

Since NO is shown to play an important role in neurotoxicity, inhibition of NO could be a possible route of intervention in the prevention of neuropathogenesis. Experimentally often used inhibitors of NOS production are synthetic arginine analogues like N^G-mono-methylarginine (NMMA), Nw-nitro-L-arginine methyl ester (L-NAME), aminoguanidine and N^G-nitroarginine.[239,258,309] They are often used in *in vitro* studies to certify the L-arginine dependent origin of NO.

Intervention of NO synthesis *in vivo* by using NOS specific inhibitors has been described in EAE using different arginine analogues e.g. aminoguanidine, L-NMMA and L-NAME.[241,300,310,311] In these experiments, the effects of these inhibitors on the clinical score of EAE were not conclusive. The aspecificity of these inhibitors for the subtypes of NOS, and thereby effects on eNOS and cNOS leading to e.g. vascular changes, may explain these different results. The search for pharmacological tools that selectively inhibit iNOS, eNOS or cNOS is currently getting much attention and thus far has yielded some agents. The

agent 7-nitroindazole is a selective cNOS inhibitor and N^G-nitro-L-arginine shows a preference for eNOS and cNOS over iNOS, whereas L-N^6-(1-iminoethyl)lysine is selective for iNOS over cNOS.[312]

Interestingly, NO can also act as a negative feedback signal on iNOS activity, by inhibiting the transcriptional induction of NOS, indicating a self-regulatory mechanism.[313,314] In cultures of rat astroglial cells norepinephrine and dexamethasone have been shown to suppress iNOS induction.[257,288,289,315] In addition, prostanoids are involved in the regulation of iNOS since prostaglandin E_2 but also cyclooxygenase inhibitors suppress iNOS expression in LPS activated rat microglial cells.[316] In addition several endogenously produced cytokines have been shown to inhibit NO production. TGFβ, IL-4 and IL-10, are known to inhibit NOS activity in monocytes[9,221,266,305,317–320] and synergistically suppress NO production.[70] TGFβ is an important modulator in the brain during development[321] and TGFβ has been demonstrated in brains of HIV patients, around brain tumours, in MS, Alzheimer's disease, brain ischaemia, peripheral nerve transections and in several experimental lesions in animals.[322–330]

Transforming growth factor β (TGFβ)

TGFβ is a 25 kDa homodimeric protein secreted by a variety of cells as a latent protein complex.[60] There are at least five distinct gene products that constitute the TGFβ family, TGFβ1 through TGFβ5 which show a high degree (70–80%) of amino acid sequence identity. The three highly homologous mammalian TGFβ isoforms are TGFβ1, TGFβ2 and TGFβ3 with relatively high sequence similarities but differences in receptor binding affinities.[331] Three different TGFβ receptors have been identified, type I to type III, which distributions are ubiquitous in various body tissues.

In a variety of studies of microglial cell cultures, TGFβ has been shown to be a potent immunosuppressive cytokine[332] and inhibits NO production by microglial cells.[333] TGFβ inhibits iNOS expression by decreasing iNOS mRNA stability and inhibiting its translation and increasing iNOS protein degradation,[334] resulting in reduced NO production.[317,335] Not only NO but also O_2^- is inhibited by TGFβ[71] and thereby the formation of the highly toxic peroxynitrite is prevented.

TGFβ is a chemotactic agent for monocytes and macrophages and is suggested to be important in the recruitment of circulating monocytes into brain tissue after damage.[336] TGFβ has protective effects in different experimental autoimmune diseases[337–339] whereas neutralizing antibodies to TGFβ1 worsen clinical severity.[340,341] During EAE, and after cerebral trauma or hypoxic-ischaemic damage, TGFβ expression is increased when neurological symptoms are


FIG. 5. Effect of immunoneutralizing of TGFβ1 and TGFβ2 on endotoxin induced expression of IL-1β and iNOS by confluent mixed glial cell cultures containing mainly astroglial cells and microglial cells. Numbers of immunopositive cells in 24 h endotoxin (1 μg/ml) stimulated mixed glial cell cultures. Different cultures were stained with the microglial cell marker GSA-I-B4-isolectin (LECT) or for IL-1β or iNOS. Data are expressed as the mean and SE (n = 3). **P < 0.005.

severe, which might indicate an inflammation limiting of TGFβ in the recovery phase thereby controlling the inflammatory reaction.[342–345]

Astroglial and microglial cells are known to constitutively produce TGFβ *in vivo*[61,324,325] and *in vitro*.[62,103–105,346,347] The isoforms TGFβ1, TGFβ2 and TGFβ3 are produced by astroglial cells *in vitro*, while microglial cells only produce the TGFβ1 isoform.[60] TGFβ production in microglial and astroglial cells is increased after TNFα[348] or IL-1[104,349] or TGFβ exposure itself.[350]

In co-cultures of astroglial cells and microglial cells bioactive TGFβ was found to inhibit iNOS expression and thereby NO production by endotoxin activated microglial cells. The presence of astroglial cells was shown to be essential for the activation of TGFβ in these co-cultures of astroglial and microglial cells[62] (see Fig. 5).

Regulation of TGFβ activity

TGFβ is produced by glial cells in a latent, inactive form[60] and forms a complex with the latency-associated protein (LAP).[351,352] Activation of latent TGFβ consists of releasing TGFβ from the LAP, which occurs after heat treatment, acidification, alkalization or proteolysis by plasmin.[351,353] Plasmin is generated by the plasminogen activator system. Plasminogen activators (PA)s are serine proteases consisting of a 50 kD urokinase-type plasminogen activator (u-PA)

FIG. 6. Activation mechanism of latent TGFβ by plasmin. Plasmin releases TGFβ from its latency associated protein (LAP) whereby active TGFβ is generated. Plasminogen is cleaved into plasmin by plasminogen activators i.e. urokinase PA (uPA) or tissue-type PA (tPA) which are inhibited by plasminogen activators inhibitors (PAI).

and a 68 kD tissue-type plasminogen activator (tPA), secreted as inactive pro-forms, which major substrate is plasminogen. uPA and tPA can cleave plasminogen into plasmin which subsequently activates latent TGFβ[354,355] (Fig. 6). These PAs are specifically inhibited by the plasminogen activator inhibitors (PAI), PAI-1, PAI-2 and PAI-3 (Table 1),[356,357] by formation of a tight complex with PAs.

Plasmin has a broad range of substrates including fibrin, fibronectin, laminin and matrix metalloproteinases (MMP). The PAs and PAIs play an important role by fine regulating the proteolytic degradation of fibrin

Table 1. Plasminogen activators and their inhibitors (adapted from Ref. 311)

	Plasminogen activators (PAs)	
	Pro form molecular weight (kDa)	Active form molecular weight (kDa)
uPA	55	33.50
tPA	70	70

	Plasminogen activators inhibitors (PAIs)	
	Molecular weight (kDa)	Substrate specificity
PAI-1	46–54	uPA=tPA
PAI-2	47–60	uPA>tPA
PAI-3	50	uPA>tPA

clots (fibrinolysis) in the circulation, mediated by plasmin[354,358] and therefore tPA is now used for the treatment of thrombotic stroke. Only recently functions for PA were found in the brain, and proteolysis of the extracellular matrix (ECM) by MMP activation, amplified by PAs, has been suggested. The breakdown of the ECM is thought to be involved in brain development and neurite outgrowth but also in neuropathology like growth and invasion of brain tumours, leukocyte infiltration in MS and EAE, breakdown of the BBB and nerve demyelination.[311]

Microglial cells secrete proteases such as elastase, uPA and secrete plasminogen[359,360] which have a direct neurotrophic effects on various types of neurones.[361] Astroglial cells can synthesize and secrete both tPA and uPA as well as PAI-1,[178,362–364] and tPA is involved in motor learning but also in Alzheimer's disease and neuronal degeneration.[365–367] PAs and PAIs have been demonstrated in cerebrospinal fluid of patients with neurological disease[368,369] and tPA expression was found[370] in MS lesions supporting a role of PA and PAI in neuropathological processes.

An important role of tPA and PAI and the regulation of TGFβ activity was shown in a glial cell coculture.[178] tPA and PAI-1 produced by astroglial cells regulated the bioactivity of TGFβ, and thereby indirectly the production of NO by microglial cells.[178] Therefore, we postulate that tPA-mediated activation of TGFβ plays an important role in neuroprotection.

Summary

In neuropathological conditions such as Alzheimer's disease, Parkinson's disease, AIDS dementia complex and multiple sclerosis, activation of microglial cells and astroglial cells is evident. Under these neuropathological conditions cellular damage in the brain is considered to arise indirectly from cytotoxic substances produced by activated glial cells. One of these toxins is NO which has been demonstrated to be produced during several neuropathological conditions. High NO levels are produced by glial cells and exert neurotoxic effects. Astroglial cells and microglial cells communicate in various ways to reduce NO production by microglial cells which is essential to maintain homeostasis in the brain. The production of TGFβ by glial cells and its activation by astrocyte-derived tPA represents one mechanism by which astroglia limit NO production in the brain.

References

1. Virchow R. Ueber das Granulierte ansehen der Wandungen der Gehirnventrikel. *Allg Z Psychiatrie* 1846; **3**: 242–250.
2. Somjen GG. Nervenkitt: notes on the history of the concept of neuroglia. *GLIA* 1988; **1**: 2–9.
3. Itagaki S, McGeer PL, Akiyama H, Zhu S, Selkoe D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease. *J Neuroimmunol* 1989; **24**: 173–182.

4. McGeer PL, Akiyama H, Itagaki S, McGeer EG. Immune system response in Alzheimer's disease. *Can J Neurol Sci* 1989; **16**: 519–527.

5. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. *Neurology* 1988; **38**: 1285–1291.

6. McGeer PL, Itagaki S, Tago H, McGeer EG. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. *Neurosci Lett* 1987; **79**: 195–200.

7. Rozemuller JM, Eikelenboom P, Pals ST, Stam FC. Microglial cells around amyloid plaques in Alzheimer's disease express leucocyte adhesion molecules of the LFA-1 family. *Neurosci Lett* 1989; **101**: 288–292.

8. Woodroofe MN, Bellamy AS, Feldman M, Davison AN, Cuzner ML. Immunocytochemical characterization of the immune reaction in the central nervous system in multiple sclerosis. Possible role for microglia in lesion growth. *J Neurol Sci* 1986; **74**: 135–152.

9. Koka P, He K, Zack JA, Kitchen S, Peacock W, Fried I, *et al.* Human immunodeficiency virus 1 envelope proteins induce interleukin 1, tumor necrosis factor alpha, and nitric oxide in glial cultures derived from fetal, neonatal, and adult human brain. *J Exp Med* 1995; **182**: 941–952.

10. Dickson DW, Lee SC, Hatch W, *et al.* Macrophages and microglia in HIV-related CNS neuropathology. In: Price RW, Perry SW, eds. *HIV, AIDS and the Brain*. New York: Raven Press, 1994; 99–118.

11. Giulian D, Yu J, Li X, Tom D, Li J, Wendt E, *et al.* Study of receptor-mediated neurotoxins released by HIV-1-infected mononuclear phagocytes found in human brain. *J Neurosci* 1996; **16**: 3139–3153.

12. Rio-Hortega P, Microglia. In: Penfield W, ed. *Cytology and Cellular Pathology of the Nervous System, Vol. 2*. New York: Hoeber, 1932; 481–534.

13. Lawson LJ, Perry VH, Dri P, Gordon S. Heterogeneity in the distribution and morphology of microglia in the normal, adult mouse brain. *Neuroscience* 1991; **39**: 151–170.

14. Murabe Y, Sano Y. Morphological studies on neuroglia. *Cell Tissue Res* 1982; **225**: 469–485.

15. Ling E, Wong W. The origin and nature of ramified and amoeboid microglia: a historical review and current concepts. *GLIA* 1993; **7**: 9–18.

16. Boya J, Calvo JL, Carbonell AL, Borregon A. A lectin histochemistry study on the development of rat microglial cells. *J Anat* 1991; **175**: 229–236.

17. Murabe Y, Sano Y. Morphological studies on neuroglia. VII. Distribution of 'brain macrophages' in brains of neonatal and adult rats, as determined by means of immunohistochemistry. *Cell Tissue Res* 1983; **229**: 85–95.

18. Perry VH, Hume DA, Gordon S. Immunohistochemical localization of macrophages and microglia in the adult and developing mouse brain. *Neuroscience* 1985; **15**: 313–326.

19. Marty S, Dusart I, Peschanski M. Glial changes following an excitotoxic lesion in the CNS–Microglia macrophages. *Neuroscience* 1991; **45**: 529–539.

20. Leong S, Ling E. Amoeboid and ramified microglia: their interrelationship and response to brain injury. *GLIA* 1992; **6**: 39–47.

21. Killackey HP. Glia and the elimination of transient cortical projections. *Trends Neurosci* 1984; **7**: 225–226.

22. Giulian D, Chen J, Ingeman JE, George JK, Naponen M. The role of mononuclear phagocytes in wound healing after traumatic injury to adult mammalian brain. *J Neurosci* 1989; **9**: 4416–4429.

23. Stoll G, Trapp BD, Griffin JW. Macrophage function during Wallerian degeneration of rat brain optic nerve: clearance of degenerating myelin and Ia expression. *J Neurosci* 1989; **9**: 2327–2335.

24. Murabe Y, Ibata Y, Sano Y. Morphological studies on neuroglia. III. Macrophage response and 'microgliocytosis' in kainic acid-induced lesions. *Cell Tissue Res* 1981; **218**: 75–85.

25. Fujita S, Tsuchihashi Y, Kitamura T. Origin, morphology and function of the microglia. *Prog Clin Biol Res* 1981; **59A**: 141–169.

26. Imamoto K. Origin of microglia: cell transformation from blood monocytes into macrophagic amoeboid cells and microglia. *Prog Clin Biol Res* 1981; **59A**: 125–139.

27. Hickey WF, Kimura H. Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. *Science* 1988; **239**: 290–292.

28. Hickey WF, Vass K, Lassmann H. Bone marrow-derived elements in the central nervous system: an immunohistochemical and ultrastructural survey of rat chimeras. *J Neuropathol Exp Neurol* 1992; **51**: 246–256.

29. De Groot CJA, Huppes W, Sminia T, Kraal G, Dijkstra CD. Determination of the origin and nature of brain macrophages and microglial cells in mouse central nervous using non-radioactive in situ hybridization and immunoperoxidase techniques. *GLIA* 1992; **6**: 301–309.

30. Matsumoto Y, Fujiwara M. Absence of donor-type major histocompatibility complex class I antigen bearing microglia in the rat central nervous system of radiation bone marrow chimeras. *J Neuroimmunol* 1987; **17**: 71–82.

31. Ting JP, Nixon DF, Weiner LP, Frelinger JA. Brain Ia antigens have a bone marrow origin. *Immunogenetics* 1983; **17**: 295–301.

32. Schultze B, Korr H. Cell kinetic studies of different cell types in the developing and adult brain of the rat and the mouse: a review. *Cell Tissue Kinet* 1981; **14**: 309–325.

33. Graeber MB, Tetzlaff W, Streit WJ, Kreutzberg GW. Microglial cells but not astrocytes undergo mitosis following rat facial nerve axotomy. *Neurosci Lett* 1988; **85**: 317–321.

34. Alliot F, Lecain E, Grima B, Pessac B. Microglial progenitors with a high proliferative potential in the embryonic and adult mouse brain. *Proc Natl Acad Sci USA* 1991; **88**: 1541–1545.

35. Lawson LJ, Perry VH, Gordon S. Turnover of resident microglia in the normal adult mouse brain. *Neuroscience* 1992; **48**: 405–415.

36. Streit WJ, Graeber MB, Kreutzberg GW. Functional plasticity of microglia: a review. *GLIA* 1988; **1**: 301–307.

37. Lassmann H, Schmied M, Vass K, Hickey WF. Bone marrow derived elements and resident microglia in brain inflammation. *GLIA* 1993; **7**: 19–24.

38. Kibayashi K, Mastri AR, Hirsch CS. Neuropathology of human immuno-deficiency virus infection at different disease stages. *Hum Pathol* 1996; **27**: 637–642i.

39. Budka H, Costianzi G, Cristina A, Lechi A, Parravicini C, Trabattoni R, *et al.* Brain pathology induced by infection with the human immunodeficiency virus (HIV). A histological, immunocytochemical, and electron microscopical study of 100 autopsy cases. *Acta Neuropathol* 1987; **75**: 185–198.

40. Calvo C, Yoshimura T, Gelman M, Mallat M. Production of monocyte chemotactic protein-1 by rat brain macrophages. *Eur J Neurosci* 1996; **8**: 1725–1734.

41. Frei K, Siepl C, Groscurth P, Bodmer S, Fontana A. Immunobiology of microglial cells. *Ann NY Acad Sci* 1987; **540**: 218–227.

42. Perry VH, Gordon S. Macrophages and microglia in the nervous system. *TINS* 1988; **11**: 273–277.

43. Perry VH, Gordon S. Modulation of CD4 antigen on macrophages and microglia in rat brain. *J Exp Med* 1987; **166**: 1138–1143.

44. Bo L, Mork S, Kong PA, Nyland H, Pardo CA, Trapp BD. Detection of MHC class II-antigens on macrophages and microglia, but not on astrocytes and endothelia in active multiple sclerosis lesions. *J Neuroimmunol* 1994; **51**: 135–146.

45. Tooyama I, Kimura H, Akiyama H, McGeer PL. Reactive microglia express class I and class II major histocompatibility complex antigens in Alzheimer's disease. *Brain Res* 1990; **523**: 273–280.

46. McRae A, Gilland E, Bona E, Hagberg H. Microglia activation after neonatal hypoxic-ischaemia. *Dev Brain Res* 1995; **84**: 245–252.

47. Suzumura A, Sawada M, Marunouchi R, Yamamoto H. Proliferation of microglia with IL-4. *Neuroimmunol* 1993; **1**: 248–263.

48. Oehminchen M. Inflammatory cells in the central nervous system: an integrating concept based on recent research in pathology, immunology, and forensic medicine. In: *Progress in Neuropathology*. New York: Raven Press, 1983; 277–296.

49. Yao J, Harvath L, Gilbert DL, Colton CA. Chemotaxis by a CNS macrophage, the microglia. *J Neurosci* 1990; **27**: 36–42.

50. Giulian D, Baker TJ, Shih LN, Lachman LB. Interleukin 1 of the central nervous system is produced by ameboid microglia. *J Exp Med* 1986; **164**: 594–604.

51. Vincent VAM, Van Dam A-M, Persoons JHA, Schotanus K, Steinbusch HWM, Schoffelmeer ANM, *et al.* Gradual inhibition of inducible nitric oxide synthase but not of interleukin-1β production in rat microglial cells of endotoxin-treated mixed glial cell cultures. *GLIA* 1996; **17**: 94–102.

52. Yao J, Keri JE, Taffs RE, Colton CA. Characterization of interleukin-1 production by microglia in culture. *Brain Res* 1992; **591**: 88–93.

53. Hetier E, Ayala J, Denefle P, Bousseau A, Rouget P, Mallat M, *et al.* Brain macrophages synthesize interleukin-1 and interleukin-1 mRNAs in vitro. *J Neurosci Res* 1988; **21**: 398–397.

54. Hetier E, Ayala J, Bousseau A, Prochiantz A. Modulation of interleukin-1 and tumor necrosis factor expression by β-adrenergic agonists in mouse ameboid microglial cells. *Exp Brain Res* 1991; **86**: 407–413.

55. Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, *et al.* Brain interleukin 1 and S-100 immunoreactivity are elevated in down syndrome and Alzheimer's disease. *Proc Natl Acad Sci USA* 1989; **86**: 7611–7615.

56. Sawada M, Kondo N, Suzumura A, Marunouchi T. Production of tumour necrosis factor-alpha by microglia and astrocytes in culture. *Brain Res* 1989; **491**: 394–397.

57. Chao CC, Hu S, Close K, Choi CS, Molitor TW, Novick WJ, *et al.* Cytokine release from microglia: differential inhibition by pentoxifylline and dexametasone. *J Infect Dis* 1992; **166**: 847–853.

58. Sebire G, Emilie D, Wallon C, Hery C, Devergne O, Delfraissy J, *et al.* In vitro production of IL-6, IL-1β, and tumor necrosis factor-alpha by human embryonic microglial and neural cells. *J Immunol* 1993; **150**: 1517–1523.

59. Lee SC, Liu W, Dickson DW, Brosnan CF, Berman JW. Cytokine production by human fetal microglia and astrocytes. *J Immunol* 1993; **150**: 2659–2667.

60. Constam DB, Philipp J, Malipiero UV, ten Rijke P. Differential expression of transforming growth factor-β1, -β2, and -β3 by glioblastoma cells, astrocytes, and microglia. *J Immunol* 1992; **148**: 1404–1410.

61. Kiefer R, Gold R, Gehrmann J, Lindholm D, Wekerle H, Kreutzberg GW. Transforming growth factor beta expression in reactive spinal cord microglia and meningeal inflammatory cells during experimental

allergic neuritis. *J Neurosci Res* 1993; **36**: 391–398.

62. Vincent VAM, Tilders FJH, Van Dam A-M. Inhibition of endotoxin-induced nitric oxide synthase production in microglial cells by the presence of astroglial cells: a role for transforming growth factor β. *GLIA* 1997; **19**: 190–198.

63. Minghetti L, Polazzi E, Nicolini A, Creminon C, Levi G. Interferon-gamma and nitric oxide down-regulate lipopolysaccharide-induced prostanoid production in cultured rat microglial cells by inhibiting cyclooxygenase-2 expression. *J Neurochem* 1996; **66**: 1963–1970.

64. Giulian D, Corpuz M, Richmond B, Wendt E, Hall ER. Activated microglia are the principal source of thromboxane in the central nervous system. *Neurochem Int* 1996; **29**: 65–76.

65. Matsuo M, Hamasaki Y, Fujiyama F, Miyazaki S. Eicosanoids are produced by microglia, not by astrocytes, in rat glial cell cultures. *Brain Res* 1995; **685**: 201–204.

66. Sawada M, Suzumura A, Itoh Y, Marunouchi T. Production of interleukin-5 by mouse astrocytes and microglia in culture. *Neurosci Lett* 1993; **155**: 175–178.

67. Williams K, Dooley N, Ulvestad E, Becher B, Antel JP. IL-10 production by adult human derived microglial cells. *Neurochem Int* 1996; **29**: 55–64.

68. Mizuno T, Sawada M, Marunouchi T, Suzumura A. Production of interleukin-10 by mouse glial cells in culture. *Biochem Biophys Res Commun* 1994; **205**: 1907–1915.

69. Cunha FQ, Moncada S, Liew FY. Interleukin-10 (IL-10) inhibits the induction of nitric oxide synthase by interferon-gamma in murine macrophages. *Biochem Biophys Res Comm* 1992; **182**: 1155–1159.

70. Oswald IP, Gazzinelli RT, Sher A, James SL. IL-10 synergizes with IL-4 and transforming growth factor-β to inhibit macrophage cytotoxic activity. *J Immunol* 1992; **148**: 3578–3582.

71. Hu S, Sheng WS, Peterson PK, Chao CC. Cytokine modulation of murine microglial cell superoxide production. *GLIA* 1995; **13**: 45–50.

72. Raff MC, Abney ER, Miller RH. Two glial cell lineages diverge prenatally in the rat optic nerve. *Dev Biol* 1984; **106**: 53–64.

73. Cameron RS, Rakic P. Glial cell lineage in the cerebral cortex: a review and synthesis. *GLIA* 1991; **4**: 124–137.

74. Misson J, Takahashi T, Caviness VS Jr. Ontogeny of radial and other astroglial cells in murine cerebral cortex. *GLIA* 1991; **4**: 138–148.

75. Goldman JE, Vaysse PJ. Tracing glial cell lineages in the mammalian forebrain. *GLIA* 1991; **4**: 149–156.

76. Noble M. Points of controversy in the 0–2A lineage: clocks and type-2 astrocytes. *GLIA* 1991; **4**: 157–164.

77. Martin PM, O'Callaghan JP. A direct comparison of GFAP immunocytochemistry and GFAP concentration in various regions of ethanol-fixed rat and mouse brain. *J Neurosci Meth* 1995; **58**: 181–192.

78. Eng LF, DeArmond SJ. Immunocytochemical studies of astrocytes in normal development and disease. *Adv Cell Neurobiol* 1982; **3**: 145–171.

79. Akimoto J, Itoh H, Miwa T, Ikeda K. Immunohistochemical study of glutamine synthetase expression in early glial development. *Dev Brain Res* 1993; **72**: 9–14.

80. Caldini M, Rolland B, Fages C, Tardy M. Glutamine synthetase activity during mouse brain development. *Experientia* 1982; **38**: 1199–1202.

81. Shehab SAS, Cronly-Dillon JR, Nona SN, Stafford CA. Preferential histochemical staining of protoplasmic and fibrous astrocytes in rat CNS with GFAP antibodies using different fixatives. *Brain Res* 1990; **518**: 347–352.

82. Miller RH, Raff MC. Fibrous and protoplasmic astrocytes are biochemically and developmentally distinct. *J Neurocytol* 1984; **15**: 187–192.

83. Ogawa M, Araki M, Nagatsu I, Yoshida M. Astroglial cell alteration caused by neurotoxins: immunohistochemical observations with antibodies to glial fibrillary acidic protein, laminin, and tyrosine hydroxylase. *Exp Neur* 1989; **106**: 187–196.

84. Dell'Anna ME, Geloso MC, Draisci G, Luthman J. Transient changes in Fos and GFAP immunoreactivity precede neuronal loss in the rat hippocampus following neonatal anoxia. *Exp Neur* 1995; **131**: 144–156.

85. O'Callaghan JP. Assessment of neurotoxicity: use of glial fibrillary acidic protein as a biomarker. *Biomed Environ Sci* 1991; **4**: 197–206.

86. O'Callaghan JP, Jensen KF. Enhanced expression of glial fibrillary acidic protein and the cupric silver degeneration reaction can be used as sensitive and early indicators of neurotoxicity. *Neuro Tox* 1992; **13**: 113–122.

87. Levi-Montalcini R, Angletti PU. Nerve growth factor. *Physiol Rev* 1968; **48**: 534–569.

88. Gonzalez D, Les Dees W, Kiney JK, Ojeda SR, Saneto RP. Expression of β-nerve growth factor in cultured cells derived from the hypothalamus and cerebral cortex. *Brain Res* 1990; **511**: 249–258.

89. Friedman WJ, Larkfors L, Ayer-le-Lievre C, Ebendal T, Olson L, Persson H. Regulation of beta nerve growth factor expression by inflammatory mediators in hippocampal cultures. *J Neurosci Res* 1990; **27**: 374–382.

90. Lindholm D, Heumann R, Meyer M, Thoenen H. Interleukin-1 regulates synthesis of nerve growth factor in non-neuronal cells of rat sciatic nerve. *Nature* 1987; **330**: 658–659.

91. Bandtlow CE, Meyer M, Lindholm D, Sprangler M, Heuman R, Thoenen

H. Regional and cellular codistribution of interleukin-1 beta and nerve growth factor mRNA in the adult rat brain: possible relationship to the regulation of nerve growth factor synthesis. *J Cell biol* 1990; **111**: 1701–1711.

92. Spranger M, Lindholm D, Bandtlow C, Heumann R, Gnahn H, Naher-Noe M, *et al*. Regulation of nerve growth factor (NGF) synthesis in the rat central nervous system: comparison between the effects of interleukin-1 and various growth factors in astrocyte cultures in vivo. *Eur J Neurosci* 1990; **2**: 69–76.

93. Gadient RA, Cron KC, Otten U. Interleukin-1β and tumor necrosis factor-alpha synergistically stimulate nerve growth factor (NGF) release from cultured rat astrocytes. *Neurosci Lett* 1990; **117**: 335–340.

94. Awatsuji H, Furukawa Y, Hirota M, Murakami Y, Nii S, Furakawa S, *et al*. Interleukin-4 and −5 as modulators of nerve growth factor synthesis/secretion in astrocytes. *J Neurosci Res* 1993; **34**: 539–545.

95. Rudge JS, Pasnikowski EM, Hoslst P, Lindsay RM. Changes in neurotrophic factor expression and receptor activation following exposure of hippocampal neuron/astrocyte cocultures to kainic acid. *J Neurosci* 1995; **15**: 6856–6867.

96. Mocchetti I, Wrathall JR. Neurotrophic factors in central nervous system trauma. *J Neurotrauma* 1995; **12**: 853–870.

97. Fontana A, Kristensen F, Dubs R, Gemsa D, Weber E. Production of prostaglandin E and an interleukin-1 like factor by cultured astrocytes and C6 glioma cells. *J Immunol* 1982; **129**: 2413–2419.

98. Nieto-Sampedro M, Berman MA. Interleukin-1-like activity in rat brain: sources, targets, and effect of injury. *J Neurosci Res* 1987; **17**: 214–219.

99. Fontana A, Grob PJ. Astrocyte-derived interleukin-1-like factors. *Lymph Res* 1984; **3**: 11–16.

100. Fontana A, McAdam KPWJ, Kristensen F, Weber E. Biological and biochemical characterization of an interleukin 1-like factor from rat C6 glioma cells. *Eur J Immunol* 1983; **13**: 685–689.

101. Sawada M, Suzumura A, Marunouchi T. TNF-alpha induces IL-6 production by astrocytes but not by microglia. *Brain Res* 1992; **583**: 296–299.

102. Frei K, Bodmer S, Schwerdel C, Fontana A. Astrocytes of the brain synthesize Interleukin 3-like factors. *J Immunol* 1985; **135**: 4044–4047.

103. da Cunha A, Jackson RW, Vitkovic L. HIV-1 non-specifically stimulates production of transforming growth factor-β1 transfer in primary astrocytes. *J Neuroimmunol* 1995; **60**: 125–133.

104. da Cunha A, Vitkovic L. Transforming growth factor-beta 1 (TGFβ1) expression and regulation in rat cortical astrocytes. *J Neuroimmunol* 1992; **36**: 157–169.

105. Morganti-Kossmann MC, Kossmann T, Brandes ME, Mergenhagen SE, Wahl SM. Autocrine and paracrine regulation of astrocyte function by transforming growth factor-β. *J Neuroimmunol* 1992; **39**: 163–174.

106. Lee SC, Dickson DW, Brosnan CF. Interleukin-1, nitric oxide and reactive astrocytes. *Brain Behav Immun* 1995; **9**: 345–354.

107. Moline-Holgado F, Lledo A, Guaza C. Evidence for cyclooxygenase activation by nitric oxide in astrocytes. *GLIA* 1995; **15**: 167–172.

108. Brenner T, Yamin A, Abramsky O, Gallily R. Stimulation of tumor necrosis factor-alpha production by mycoplasmas and inhibition by dexametasone in cultured astrocytes. *Brain Res* 1993; **608**: 273–279.

109. Giulian D, Vaca K, Johnson B. Secreted peptides as regulators of neuron-glia and glia-glia interactions in the developing nervous system. *J Neurosci Res* 1988; **21**: 487–500.

110. Lee SC, Brosnan CF, Dickson DW. GM-CSF promotes proliferation of human fetal and adult microglia in primary cultures. *GLIA* 1994; **12**: 309–318.

111. Giulian D, Johnson B, Krebs JF, George JK, Tapscott M. Microglial mitogens are produced in the developing and injured mammalian brain. *J Cell Biol* 1991; **112**: 323–333.

112. Lafortune L, Nalbantoglu J, Antel JP. Expression of tumor necosis factor alpha (TNF alpha) and interleukin 6 (IL-6) mRNA in adult human astrocytes: comparison with adult microglia and fetal astrocytes. *J Neuropathol Exp Neurol* 1996; **55**: 515–521.

113. Aloisi F, Borsellino G, Samoggia P, Testa U, Chelucci C, Russo G, *et al*. Astrocyte cultures from human embryonic brain: characterization and modulation of surface molecules by inflammatory cytokines. *J Neurosci Res* 1992; **32**: 494–506.

114. Fontana A, Fierz W, Wekerle H. Astrocytes present myelin basic protein to encephalitogenic T-cell lines. *Nature* 1984; **307**: 273–276.

115. Lassmann H, Vass K, Brunner C, Seitelberger F. Characterization of inflammatory infiltrates in experimental allergic encephalomyelitis. *Progr Neuropathol* 1986; **6**: 33.

116. Giulian D, Woodward J, Young DG, Krebs JF, Lachman LB. Interleukin-1 injected into mammalian brain stimulates astrogliosis and neovascularization. *J Neurosci* 1988; **8**: 2485–2490.

117. Giulian D, Young DG, Woodward J, Brown DC, Lachman LB. Interleukin-1 is an astroglial growth factor in the developing brain. *J Neurosci* 1988; **8**: 709–714.

118. Giulian D, Tapscott MJ. Immunoregulation of cells within the central nervous system. *Brain, Behavior and Immunity* 1988; **2**: 352–358.

119. Giulian D, Baker TJ. Peptides released by ameboid microglia regulate astroglial proliferation. *J Cell Biol* 1985; **101**: 2411–2415.

120. Giulian D, Lachman LB. Interleukin-1 stimulation of astroglial proliferation after brain injury. *Science* 1985; **228**: 497–499.
121. Berkenbosch F. Macrophages and astroglial interactions in repair to brain injury. *Ann NY Acad Sci USA* 1992; **650**: 186–190.
122. Giulian D, Li J, Li X, George J, Rutecki PA. The impact of microglia-derived cytokines upon gliosis in the CNS. *Dev Neurosci* 1994; **16**: 128–136.
123. Frei K, Bodmer S, Schwerdel C, Fontana A. Astrocyte-derived interleukin 3 as a growth factor for microglial cells and peritoneal macrophages. *J Immunol* 1986; **137**: 3521–3527.
124. Thery C, Stanley ER, Mallat M. Interleukin 1 and tumor necrosis factor-alpha stimulate the production of colony-stimulating factor 1 by murine astrocytes. *J Neurochem* 1992; **59**: 1183–1186.
125. Liu W, Brosnan CF, Dickson DW, Lee SC. Macrophage colony-stimulating factor mediates astrocyte-induced microglial ramification in human fetal central nervous system culture. *Am J Pathol* 1994; **145**: 48–53.
126. Giulian D, Ingeman JE. Colony-stimulating factors as promotors of ameboid microglia. *J Neurosci* 1988; **8**: 4707–4717.
127. Sawada M, Suzumura A, Yamamoto H, Marunouchi T. Activation and proliferation of the isolated microglia by colony stimulating factor-1 and possible involvement of protein kinase C. *Brain Res* 1990; **509**: 119–124.
128. Suzumura A, Marunouchi T, Yamamoto H. Morphological transformation of microglia in vitro. *Brain Res* 1991; **545**: 301–306.
129. Tanaka J, Maeda N. Microglial ramification requires nondiffusible factors derived from astrocytes. *Exp Neurol* 1996; **137**: 367–375.
130. Sievers J, Parwaresch R, Wottge H. Blood monocytes and spleen macrophages differentiate into microglia-like cells on monolayers of astrocytes: morphology. *GLIA* 1994; **12**: 245–258.
131. Schmidtmayer J, Jacobsen C, Miksch G, Sievers J. Blood monocytes and spleen macrophages differentiate into microglia-like cells on monolayers of astrocytes: membrane currents. *GLIA* 1994; **12**: 259–267.
132. Griffin WST, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, *et al.* Brain interleukin-1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. *Proc Natl Acad Sci USA* 1989; **86**: 7611–7615.
133. Hertz L. Neuronal-astrocytic interactions in brain development, brain function and brain disease. *Adv Exp Med Biol* 1991; **296**: 143–159.
134. Brenneman DE, Schultzberg M, Bartfai T, Gozes I. Cytokine regulation of neuronal survival. *J Neurochem* 1992; **58**: 454–460.
135. Vaca K, Wendt E. Divergent effects of astroglial and microglial secretions on neuron growth and survival. *Exp Neurol* 1992; **118**: 62–72.
136. Langeveld CH, Jongenelen CAM, Schepens E, Stoof JC, Bast A, Drukarch B. Cultured rat striatal and cortical astrocytes protect mesencephalic dopaminergic neurons against hydrogen peroxide toxicity independent of their effect on neuronal development. *Neurosci Lett* 1995; **192**: 13–16.
137. Garcia-Abreu J, Neto M, Carvalho SL, Cavalcante LA. Regionally specific properties of midbrain glia: I. Interactions with midbrain neurons. *J Neurosci Res* 1995; **40**: 471–477.
138. Dong JF, Detta A, Bakker MHM, Hitchcock ER. Direct interaction with target-derived glia enhances survival but not differentiation of human fetal mesencephalic dopaminergic neurons. *Neuroscience* 1993; **56**: 53–60.
139. Bowenkamp KE, Hoffman AF, Gerhardt GA, Henry MA, Biddle PT, Hoffner BJ, *et al.* Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons. *J Comp Neurol* 1995; **355**: 479–489.
140. Banker GA. Trophic interactions between astroglial cells and hippocampal neurons in culture. *Science* 1980; **209**: 809–810.
141. Noble M, Fok-Seang J, Cohen J. Glia are a unique substrate for the in vitro growth of central nervous system neurons. *J Neurosci* 1984; **4**: 1892–1903.
142. Schmalenbach C, Muller HW. Astroglia-neuron interactions that promote long-term neuronal survival. *J Chem Neuroanat* 1993; **6**: 229–237.
143. Hatten ME, Mason CA. Neuron-astroglial interactions in vitro and in vivo. *Trends Neuroscience* 1986; 168–174.
144. Miller C, Tsatas O, David S. Dibutyryl cAMP, interleukin-1β, and macrophage conditioned medium enhance the ability of astrocytes to promote neurite growth. *J Neurosci Res* 1994; **38**: 56–63.
145. Dugan L, Bruno VMG, Amagasu SM, Giffard RG. Glia modulate the response of murine cortical neurons to excitotoxicity: glia exacerbate AMPA neurotoxicity. *J Neurosci* 1995; **15**: 4545–4555.
146. Swanson RA, Choi DW. Glial glycogen stores affect neuronal survival during glucose deprivation in vitro. *J Cereb Blood Flow Metab* 1993; **13**: 162–169.
147. Kimelberg HK, Norenberg MD. Astrocytes. *Sci Am* 1989; **April**: 44–52.
148. Johnston PV, Roots Bl. Neuron-glial relationships. In: *Handbook of Clinical Neurology*. Amsterdam: North-Holland, 1976; 401–421.
149. Nagata K, Takei N, Nakajima K, Saito H, Kohsaka S. Microglial conditioned medium promotes survival and development of cultured mesencephalic neurons from embryonic rat brain. *J Neurosci Res* 1993;

34: 357–363.
150. Mallat M, Houlgatte R, Brachet P, Prochiantz A. Lipopolysaccharide-stimulated rat brain macrophages release NGF in vitro. *Dev Biol* 1989; **133**: 309–311.
151. Chamak B, Dobbertin A, Mallat M. Immunohistochemical detection of thrombospondin in microglia in the developing rat brain. *Neuroscience* 1995; **69**: 177–187.
152. Chamak B, Morandi V, Mallat M. Brain macrophages stimulate neurite growth and regeneration by secreting thrombospondin. *J Neurosci Res* 1994; **38**: 221–233.
153. Shimojo M, Nakajima K, Takei N, Hamanoue M, Kohsaka S. Production of basic fibroblast growth factor in cultured rat brain microglia. *Neurosci Lett* 1991; **123**: 229–231.
154. Araujo DM, Cotman CW. Basic FGF in astroglial, microglial, and neuronal cultures: characterization of binding sites and modulation of release by lymphokines and trophic factors. *J Neurosci* 1992; **12**: 1668–1678.
155. Yoshida K, Kakihana M, Chen LS, Ong M, Baird A, Gage FH. Cytokine regulation of nerve growth factor-mediated cholinergic neurotrophic activity synthesized by astrocytes and fibroblasts. *J Neurochem* 1992; **59**: 919–931.
156. Yoshida K, Gage FH. Cooperative regulation of nerve growth factor synthesis and secretion of fibroblasts and astrocytes by fibroblast growth factor and other cytokines. *Brain Res* 1992; **569**: 14–25.
157. Merill JE. Tumor necrosis factor alpha, interleukin 1 and related cytokines in brain development: normal and pathological. *Dev Neurosci* 1992; **14**: 1–10.
158. Strijbos PJLM, Rothwell NJ. Interleukin-1β attenuates excitatory amino acid-induced neurodegeneration in vitro: involvement of nerve growth factor. *J Neurosci* 1995; **15**: 3468–3474.
159. Hama T, Kushima Y, Miyamoto M, Kubota M, Takei N, Hatanaka H. Interleukin-6 improves the survival of mesencephalic catecholaminergic and septal cholinergic neurons from postnatal two-week-old rats in cultures. *Neuroscience* 1991; **40**: 445–452.
160. Akaneya Y, Takahishi M, Hatanaka H. Interleukin-1β enhances survival and interleukin-6 protects against MPP+ neurotoxicity in cultures of fetal rat dopaminergic neurons. *Exp Neurol* 1995; **136**: 44–52.
161. Giulian D, Corpuz M. Microglial secretion products and their impact on the nervous system. *Adv Neurol* 1993; **59**: 315–320.
162. Giulian D, Vaca K, Noonan CA. Secretion of neurotoxins by mononuclear phagocytes infected with HIV-1. *Science* 1990; **250**: 1593–1596.
163. Aswell K. The distribution of microglia and cell death in the fetal rat forebrain. *Dev Brain Res* 1991; **58**: 1–12.
164. Hume DA, Perry VH, Gordon S. Immunohistochemical localization of a macrophage-specific antigen in developing mouse retina: phagocytosis of dying neurons and differentiation of microglial cells to form a regular array in the plexiform layers. *J Cell Biol* 1983; **97**: 253–257.
165. Ferrer I, Bernet E, Soriano E, Del Rio T, Fonseca M. Naturally occurring cell death in the cerebral cortex of the rat and removal of dead cells by transitory phagocytes. *Neuroscience* 1990; **39**: 451–458.
166. Innocenti GM, Clarke S, Koppel H. Transitory macrophages in the white matter of the developing visual cortex. II. Development and relations with axonal pathways. *Dev Brain Res* 1983; **11**: 55–66.
167. Colton CA, Gilbert DL. Microglia, an in vivo source of reactive oxygen species in the brain. *Adv Neurol* 1993; **59**: 321–326.
168. Van Muiswinkel FL, Veerhuis R, Eikelenboom P. Amyloid β protein primes cultured rat microglial cells for an enhanced phorbol 12-myristate 13-acetate-induced respiratory burst activity. *J Neurochem* 1996; **66**: 2468–2476.
169. Banati RB, Hoppe K, Gottmann K, Kreutzberg GW. Cytotoxicity of microglia. *GLIA* 1993; **30**: 111–118.
170. Banati RB, Rothe G, Valet G, Kreutzberg GW. Detection of lysosomal cysteine proteinases in microglia: flow cytometric measurement and histochemical localization of cathepsin B and L. *GLIA* 1993; **7**: 183–191.
171. Colton AC, Gilbert DL. Production of superoxide by a CNS macrophage, the microglia. *FEBS Lett* 1987; **223**: 284–288.
172. Thery C, Chamak B, Mallat M. Free radical killing of neurons. *Eur J Neurosci* 1991; **3**: 1155–1164.
173. Dickson DW, Lee SC, Mattiace LA, Yen S, Brosnan CF. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. *GLIA* 1993; **7**: 75–83.
174. Chao CC, Hu S. Tumor necrosis factor-alpha potentiates glutamate neurotoxicity in human fetal brain cell cultures. *Dev Neurosci* 1994; **16**: 172–179.
175. Piani D, Frei K, Quang Do K, Cuenod M, Fontana A. Murine brain macrophages induce NMDA receptor mediated neurotoxicity in vitro by secreting glutamate. *Neurosci Lett* 1991; **133**: 159–162.
176. Thery C, Chamak B, Mallat M. Cytotoxic effect of brain macrophages on developing neurons. *Eur J Neurosci* 1991; **3**: 1155–1164.
177. Streit WJ. Microglial-neuronal interactions. *J Chem Neuroanat* 1993; **6**: 261–266.
178. Vincent VAM, Low ik CWGM, Verheijen JH, Tilders FJH, Van Dam A-M. Role of astrocyte-derived tissue-type plasminogen activator in the regulation of endotoxin stimulated nitric oxide production by microglial cells. *GLIA* 1998; **22**: 130–137.

179. Gower DB. Modifiers of steroid-hormone metabolism: a review of their chemistry, biochemistry and clinical applications. *J Steroid Biochem* 1974; **5**: 501–523.

180. Giulian D. Reactive glia as rivals in regulating neuronal survival. *GLIA* 1993; **7**: 102–110.

181. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. *Nature* 1980; **288**: 373–376.

182. Marletta MA. Nitric oxide synthase structure and mechanism. *J Biol Chem* 1993; **268**: 12231–12234.

183. Janssens SP, Shimouchi A, Quertermous T, Bloch DB, Block KD. Cloning an expression of a cDNA encoding human endothelium-derived relaxing factor/nitric oxide synthase. *J Biol Chem* 1992; **267**: 14519–14522.

184. Forstermann U, Schmidt HHHW, Pollock JS, Sheng H, Mitchell JA, Warner TD, et al. Isoforms of nitric oxide synthase. Characterization and purification from different cell types. *Biochem Pharmacol* 1991; **42**: 1849–1857.

185. Murphy S, Simmons ML, Agullo L, Garcia A, Feinstein DL, Galea E, et al. Synthesis of nitric oxide in CNS glial cells. *Trends Neurosci* 1993; **16**: 323–328.

186. Bredt DS, Snyder SH. Nitric oxide, a novel neuronal messenger. *Neuron* 1992; **8**: 3–11.

187. Snyder SH. Nitric oxide: first in a new class of neurotransmitters? *Science* 1992; **257**: 494–496.

188. Ignarro LJ, Gold ME, Buga GM. Basic polyamino acids rich in arginine, lysine, or ornithine cause both enhancement of and refractoriness to formation of endothelium-derived nitric oxide in pulmonary artery and vein. *Circ Res* 1989; **64**: 315–329.

189. Tzeng TB, Fung HL. Pharmacodynamic modeling of the in vitro vasodilating effects of organic mononitrates. *J Pharmacokinet Biopharm* 1992; **20**: 227–251.

190. Holscher C, Rose PR. An inhibitor of nitric oxide synthesis prevents memory formation in the chick. *Neurosci Lett* 1992; **145**: 165–167.

191. Hawkins RD. NO honey, I don't remember. *Neuron* 1996; **16**: 465–467.

192. Schuman EM, Madison DV. A requirement for the intercellular messenger nitric oxide in long-term potentiation. *Science* 1991; **254**: 1503–1506.

193. Ohno M, Yamamoto T, Watanabe S. Deficits in working memory following inhibition of hippocampal nitric oxide synthesis in the rat. *Brain Res* 1993; **632**: 36–40.

194. Bredt DS, Glatt CE, Hwang PM, Fotuhi M, Dawson TM, Snyder SH. Nitric oxide synthase protein and mRNA are discretely localized in neuronal populations of the mammalian CNS together with NADPH diaphorase. *Neuron* 1991; **7**: 615–624.

195. Benyo Z, Szabo C, Stuiver BT, Bohus B, Sandor P. Effect of chronic nitric oxide synthase blockade on local hypothalamic blood flow in rats. *Neurosci Lett* 1995; **198**: 127–130.

196. Lowenstein CJ, Glatt CS, Bredt DS, Snyder SH. Cloned and expressed macrophage nitric oxide synthase contrasts with the brain enzyme. *Proc Natl Acad Sci USA* 1992; **89**: 6711–6715.

197. Green SJ, Nacy CA. Antimicrobial and immunopathologic effects of cytokine-induced nitric oxide synthesis. *Curr Opin Infect Dis* 1993; **6**: 384–396.

198. Nathan C. Nitric oxide as a secretory product of mammalian cells. *FASEB J* 1992; **6**: 3051–3064.

199. Marletta MA, Yoon PS, Iyengar R, Leaf CD, Wishnik JS. Macrophage oxidation of L-arginine to nitrite and nitrate: nitric oxide is an intermediate. *Biochemistry* 1988; **27**: 8706–8711.

200. Koprowski H, Zheng YM, Heber-Katz E. In vivo expression of inducible nitric oxide synthase in experimentally induced neurologic diseases. *Proc Natl Acad Sci USA* 1993; **90**: 3024–3027.

201. Bolanos JP, Heales SJ, Land JM, Clark JB. Effect of peroxynitrite on the mitochondrial respiratory chain: differential susceptibility of neurons and astrocytes in primary culture. *J Neurochem* 1995; **64**: 1965–1972.

202. Boje KM, Arora PK. Microglial-produced nitric oxide and reactive nitrogen oxides mediate neuronal cell death. *Brain Res* 1992; **587**: 250–256.

203. Galea E, Feinstein DL, Reis DJ. Induction of calcium-independent nitric oxide synthase activity in primary rat glial cultures. *Proc Natl Acad Sci USA* 1992; **89**: 10945–10949.

204. Iadecola C, Xu X, Zhang F, El-Fakahany E, Ross ME. Marked induction of calcium-independent nitric oxide synthase activity after focal cerebral ischemia. *J Cereb Bood Flow Metab* 1995; **15**: 52–59.

205. Iadecola C, Zhang F, Xu S, Casey R, Ross ME. Inducible nitric oxide synthase gene expression in brain following cerebral ischemia. *J Cereb Bood Flow Metab* 1995; **15**: 378–384.

206. Choi DW. Glutamate neurotoxicity and diseases of the nervous system. *Neuron* 1988; **1**: 623–634.

207. Meldrum B, Garthwaite J. Excitatory amino acid neurotoxicity and neurodegenerative disease. *Trends Pharmacol Sci* 1990; **11**: 379–387.

208. Garthwaite J. Glutamate, nitric oxide and cell-cell signalling in the nervous system. *Trends Neurosci* 1991; **14**: 60–67.

209. Simonian NA, Coyle JT. Oxidative stress in neurodegenerative diseases. *Annu Rev Pharmacol Toxicol* 1996; **36**: 83–106.

210. Zhang J, Snyder SH. Nitric oxide in the nervous system. *Annu Rev Pharmacol Toxicol* 1995; **35**: 213–233.

211. Dawson TD, Dawson VL, Snyder SH. Molecular mechanisms of nitric oxide actions in the brain. *Ann NY Acad Sci USA* 1994; **738**: 76–85.

212. Huang Z, Huang PL, Panahian N, Dalkara T, Fishman MC, Moskowitz MA. Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase. *Science* 1994; **265**: 1883–1885.

213. Dawson VL, Dawson TM. Nitric oxide neurotoxicity. *J Chem Neuroanat* 1996; **10**: 179–190.

214. Butz EA, Hostager BS, Southern PJ. Macrophages in mice acutely infected with lymphocytic choriomeningitis virus are primed for nitric oxide synthesis. *Microbiol Pathogen* 1994; **16**: 283–295.

215. Campbell IL, Samii A, Chiang CS. Expression of inducible nitric oxide synthase. Correlation with neurology and clinical features in mice with lymphocytic choriomeningitis. *J Immunol* 1994; **153**: 3622–3629.

216. Van Dam A-M, Bauer J, Man-A-Hing WKH, Marquette C, Tilders FJH, Berkenbosch F. Appearance of inducible nitric oxide synthase in the rat central nervous system after rabies virus infection and during experimental allergic encephalmyelitis but not after peripheral administration of endotoxin. *J Neurosci Res* 1995; **40**: 251–260.

217. Zheng YM, Schafer MK, Weihe E, Sheng H, Corisdeo S, Fu ZF, et al. Severity of neurological signs and degree of inflammatory lesions in the brains of rats with Borna disease correlate with the induction of nitric oxide synthase. *J Virol* 1993; **67**: 5786–5791.

218. Korytko PJ, Boje KMK. Pharmacological characterization of nitric oxide production in a rat model of meningitis. *Neuropharmacology* 1996; **35**: 231–237.

219. Gazzinelli RT, Eltoum I, Wynn TA, Sher A. Acute cerebral toxoplasmosis is induced by in vivo neutralization of TNF-alpha and correlates with the downregulated expression of inducible nitric oxide synthase and other markers of macrophage activation. *J Immunol* 1993; **151**: 3672–3681.

220. Bo L, Dawson TM, Wesselingh S, Mork S, Choi S, Kong PA, et al. Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. *Ann Neurol* 1994; **36**: 781–786.

221. Merrill JE, Ignarro LJ, Sherman MP, Melinek J, Lane TE. Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. *J Immunol* 1993; **151**: 2132–2141.

222. Chao CC, Hu S, Molitor TW, Shaskan EG, Peterson PK. Activated microglia mediate neuronal cell injury via a nitric oxide mechanism. *J Immunol* 1992; **149**: 2736–2741.

223. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. *Proc Natl Acad Sci USA* 1990; **87**: 1620–1624.

224. Zhang J, Dawson VL, Dawson TM, Snyder SH. Nitric oxide activation op poly (ADP-ribose) synthase in neurotoxicity. *Science* 1994; **263**: 687–689.

225. Bolanos JP, Peuchen S, Heales SJR, Land JM, Clark JB. Nitric oxide-mediated inhibition of the mitochondrial respiratory chain in cultured astrocytes. *J Neurochem* 1994; **63**: 910–916.

226. Reif DW, Simmons RD. Nitric oxide mediates iron release from ferritin. *Arch Biochem Biophys* 1990; **283**: 537–541.

227. Stuehr DJ, Nathan CF. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. *J Exp Med* 1989; **169**: 1543–1555.

228. Lipton SA, Singel DJ, Stamler JS. Nitric oxide in the central nervous system. *Prog Br Res* 1994; **103**: 359–364.

229. Bonfoco E, Krainc D, Ankarcrona M, Nicotera P, Lipton S. Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with NMDA or nitric oxide/superoxide in cortical cell cultures. *Proc Natl Acad Sci USA* 1995; **92**: 7162–7166.

230. Estevez AG, Radi R, Barbeito L, Shin JT, Thompson JA, Beckman JS. Peroxynitrite-induced cytotoxicity in PC12 cells: evidence for an apoptotic mechanism differentially modulated by neurotrophic factors. *J Neurochem* 1995; **65**: 1543–1550.

231. Mitrovic B, Ignarro LJ, Vinters HV, Akers MA, Schmid I, Uittenbogaart CL, et al. Nitric oxide induces necrotic but not apoptotic cells in oligodendrocytes. *Neuroscience* 1995; **65**: 531–539.

232. Peunova N, Enikolopov G. Amplification of calcium-induced gene transcription by nitric oxide in neuronal cells. *Nature* 1993; **364**: 450–453.

233. Nicotera P, Bonfoco E, Brune B. Mechanisms for nitric oxide-induced cell death: involvement of apoptosis. *Adv Neuroimm* 1995; **5**: 411–420.

234. Dorheim MA, Tracey WR, Pollock JS, Grammas P. Nitric oxide synthase activity is elevated in brain microvessels in Alzheimer's disease. *Biochem Biophys Res Commun* 1994; **205**: 659–665.

235. Vodovotz Y, Lucia MS, Flanders C, Chesler L, Xie QS, Smith TW, Weidner J, et al. Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease. *J Exp Med* 1996; **184**: 1425–1433.

236. Sherman MP, Griscavage JM, Ignarro LJ. Nitric oxide-mediated neuronal injury in multiple sclerosis. *Med Hypotheses* 1992; **39**: 143–146.

237. Cross AH, Keeling RM, Goorha S, San M, Rodi C, Wyatt PS, et al. Inducible nitric oxide synthase gene expression and enzyme activity correlate with disease activity in murine experimental autoimmune

encephalomyelitis. *J Neuroimmunol* 1996; **71**: 145–153.

238. Bagasra O, Michaels FH, Mu Zheng Y, Bobroski LE, Spitsin SV, Fang Fu Z, *et al.* Activation of the inducible form of nitric oxide synthase in the brains of patients with multiple sclerosis. *Proc Natl Acad Sci USA* 1995; **92**: 12041–12045.

239. Brosnan CF, Battistini L, Raine CS, Dickson DW, Casedevall A, Lee SC. Reactive nitrogen intermediates in human neuropathology: an overview. *Dev Neurosci* 1994; **16**: 152–161.

240. De Groot CJA, Ruuls SR, Theeuwes JWM, Dijkstra CD, Van der Valk P. Immunocytochemical characterization of the expression of inducible and constitutive isoforms of nitric oxide synthase in demyelinating multiple sclerosis lesions. *J Neuropathol Exp Neurol* 1997; **56**: 10–20.

241. Zhao W, Tilton RG, Corbett JA, McDaniel ML, Misko TP, Williamson JR, *et al.* Experimental allergic encephalomyelitis in the rat is inhibited by aminoguanidine, an inhibitor of nitric oxide synthase. *J Neuroimmunol* 1996; **64**: 123–133.

242. Beck J, Rondot P, Catinot L, Falcoff E, Kirchner H, Wietzerbin J. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations. *Acta Neurol Scand* 1988; **78**: 318–330.

243. Hofman FM, Hinton DR, Johnson K, Merrill JE. Tumor necrosis factor identified in multiple sclerosis brain. *J Exp Med* 1989; **170**: 607–612.

244. Merrill JE, Strom SR, Ellison GW, Myers LW. In vitro study of mediators of inflammation in multiple sclerosis. *J Clin Immunol* 1989; **9**: 84–96.

245. Panitch HS, Hirsch RL, Schindler J, Johnson KP. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. *Neurology* 1987; **37**: 1097–1100.

246. Adamson DC, Wildemann B, Sasaki M, Glass JD, McArthur JC, Christov VI, *et al.* Immunologic NO synthase: elevation in severe AIDS dementia and induction by HIV-1 gp41. *Science* 1996; **274**: 1917–1920.

247. Nuovo GJ, Lynn Alfieri M. AIDS dementia is associated with massive, activated HIV-1 infection and concomitant expression of several cytokines. *Mol Med* 1996; **2**: 358–366.

248. Lane TE, Buchmeier J, Watry DD, Fox HS. Expression of inflammatory cytokines and inducible nitric oxide synthase in brains of SIV-infected rhesus monkeys: applications to HIV-induced central nervous system disease. *Mol Med* 1996; **2**: 27–37.

249. Vazeux R, Brousse N, Jarry A, Henin D, Marche C, Vedrenne C, *et al.* AIDS subacute encephalitis; identification of HIV-infected cells. *Am J Pathol* 1987; **126**: 403–410.

250. Lee SC, Dickson DW, Liu W, Brosnan CF. Induction of nitric oxide synthase activity in human astrocytes by interleukin-1β and interferon-gamma. *J Neuroimmunol* 1993; **46**: 19–24.

251. Maddon PJ, Dalgleish AG, McDougal JS, Clampham PR, Weiss RA, Axel R. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. *Cell* 1986; **47**: 333–348.

252. Genis P, Jett M, Bernton EW, Boyle T, Gelbard HA, Dzenko K, *et al.* Cytokines and arachidonic metabolites produced during human immunodeficiency virus (HIV)-infected macrophage-astroglia interactions: implications for the neuropathogenesis of HIV disease. *J Exp Med* 1992; **176**: 1703–1718.

253. Yeung MC, Pulliam L, Lau AS. The HIV envelope protein gp120 is toxic to human brain-cell cultures through the induction of interleukin-6 and tumor necrosis factor-alpha. *AIDS* 1995; **9**: 137–143.

254. Epstein LG, Gendelman HE. Human immunodeficiency virus type 1 infection of the nervous system: pathogenetic mechanisms. *Ann Neurol* 1993; **33**: 429–436.

255. Wiley CA, Achim CL, Schrier RD, Heyes MP, McCutchan JA, Grant I. Relationship of cerebrospinal fluid immune activation associated factors to HIV encephalitis. *AIDS* 1992; **6**: 1299–1307.

256. Achim CL, Heyes M, Wiley CA. Quantitation of human immunodeficiency virus, immune activation factors, and quinolinic acid in AIDS brains. *J Clin Invest* 1993; **91**: 2769–2775.

257. Pietraforte D, Tritarelli E, Testa U, Minetti M. Gp120 HIV envelope glycoprotein increases the production of nitric oxide in human monocyte-derived macrophages. *J Leukoc Biol* 1994; **55**: 175–182.

258. Mollace V, Colasanti M, Persichini T, Bagetta G, Lauro GM, Nistico G. HIV gp120 glycoprotein stimulates the inducible isoform of NO synthase in human cultured astrocytoma cells. *Biochem Biophys Res Comm* 1993; **194**: 439–445.

259. Chao CC, Hu S, Sheng WS, Bu D, Bukrinsky MI, Peterson PK. Cytokine-stimulated astrocytes damage human neurons via a nitric oxide mechanism. *GLIA* 1996; **16**: 276–284.

260. Dawson VL, Bahmbhatt HP, Mong JA, Dawson TM. Expression of inducible nitric oxide synthase causes delayed neurotoxicity in primary mixed neuronal-glial cortical cultures. *Neuropharmacology* 1994; **33**: 1425–1430.

261. Dawson TM, Zhang J, Dawson VL, *et al.* Nitric oxide: cellular regulation and neuronal injury. In: Seil F, ed. *Progress in Brain Research*. Amsterdam: Elsevier Science, 1994; 365–369.

262. Wesselingh SL, Takahashi K, Glass KD, McArthur JC, Griffin JW, Griffin DE. Cellular localization of tumor necrosis factor mRNA in neurological tissue from HIV-infected patients by combined reverse transcriptase/polymerase chain reaction in situ hybridization and immunohistochem-

263. istry. *J Immunol* 1997; **74**: 1–8.

264. Yoshioka M, Bradley WG, Shapshak P, Nagano I, Stewart RV, Xin K, *et al.* Role of immune activation and cytokine expression in HIV-1-associated neurologic diseases. *Adv Neuroimmunol* 1995; **5**: 335–358.

264. Perrella O, Finelli L, Carrieri PB. The role of cytokines in AIDS-dementia complex. *Acta Neurologica* 1992; **14**: 342–344.

265. Sippy BD, Hofman FM, Wallach D, Hinton DR. Increased expression of tumor necrosis factor-alpha receptors in the brains of patients with AIDS. *J AIDS Hum Retrovir* 1995; **10**: 511–521.

266. Bukrinsky MI, Nottet HSLM, Schmidtmayerova H, Dubrovsky L, Flanagan CR, Mullins ME, *et al.* Regulation of nitric oxide synthase activity in human immunodeficiency virus type 1 (HIV-1)-infected monocytes: implications for HIV-associated neurological disease. *J Exp Med* 1995; **181**: 735–745.

267. Colasanti M, Persichini T, Di Pucchio T, Gremo F, Lauro GM. Human ramified microglial cells produce nitric oxide upon Escherichia coli lipopolysaccharide and tumor necrosis factor alpha stimulation. *Neurosci Lett* 1995; **200**: 144–146.

268. Dighiero P, Reux I, Hauw J, Fillet AM, Courtois Y, Goureau O. Expression of inducible nitric oxide synthase in cytomegalovirus-infected glial cells of retinas from AIDS patients. *Neurosci Lett* 1994; **166**: 31–34.

269. Hunot S, Boissiere F, Faucheux B, Brugg B, Mouatt-Prigent A, Agid Y, *et al.* Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. *Neuroscience* 1996; **72**: 355–363.

270. Connop BP, Boegman RJ, Beninger RJ, Jhamandas K. Attenuation of malonate-induced degeneration of the nigrostriatal pathway by inhibitors of nitric oxide synthase. *Neuropharmacology* 1996; **35**: 459–465.

271. Ischirpoulos H, Duran D, Horwitz J. Peroxynitrite-mediated inhibition of DOPA synthesis in PC12 cells. *J Neurochem* 1995; **65**: 2366–2372.

272. Paakkari I, Lindsberg P. Nitric oxide in the central nervous system. *Ann Med* 1995; **27**: 369–377.

273. Endoh M, Maiese K, Wagner JA. Expression of the inducible form of nitric oxide synthase by reactive astrocytes after transient global ischemia. *Brain Res* 1994; **651**: 92–100.

274. Nowicki JP, Duval D, Poignet H, Scatton B. Nitric oxide mediates neuronal death after focal cerebral ischemia in the mouse. *Eur J Pharmacol* 1991; **204**: 339–340.

275. Bertini G, Savio T, Zaccheo D, Schmidt HHHW, Bentivoglio M. NADPH-diaphorase activity in brain macrophages during postnatal development in the rat. *Neuroscience* 1996; **70**: 287–293.

276. Wallace MN, Fredens K. Activated astrocytes of the mouse hippocampus contain high levels of NADPH-diaphorase. *NeuroReport* 1992; **3**: 953–956.

277. Glenn JA, Jordan FL, Thomas WE. Further studies on the identification of microglia in mixed brain cell cultures. *Brain Res Bull* 1989; **22**: 1049–1052.

278. Hassan NF, Campbell DE, Rifat S, Douglas SD. Isolation and characterization of human fetal brain-derived microglia in in vitro culture. *Neuroscience* 1991; **41**: 149–158.

279. Gebicke-Haerter PJ, Bauer J, Schobert A, Northoff H. Lipopolysaccharide-free conditions in primary astrocyte cultures allow growth and isolation of microglial cells. *J Neurosci* 1989; **9**: 183–194.

280. Thiele DL, Kurosaka M, Lipsky PE. Phenotype of the accessory cell necessary for mitogen-stimulated T and B cell responses in human peripheral blood: delineation by its sensitivity to the lysosomotropic agent, L-leucine methyl ester. *J Immunol* 1983; **131**: 2282–2290.

281. McCarthy KD, Vellis de H. Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. *J Cell Biol* 1980; **85**: 890–902.

282. Schwartz JP, Wilson DJ. Preparation and characterization of type 1 astrocytes cultured from adult rat cortex, cerebellum and striatum. *GLIA* 1992; **5**: 75–80.

283. Frei K, Lins H, Schwerdel C, Fontana A. Antigen presentation in the central nervous system: the inhibitory effect of IL-10 on MHC Class II expression and production of cytokines depends on the inducing signals and the type of cell analyzed. *J Immunol* 1994; **152**: 2720–2728.

284. Giulian D, Baker TJ. Characterization of ameboid microglia isolated from developing mammalian brain. *J Neurosci* 1986; **6**: 2163–2178.

285. Suzumura A, Mezitis SGE, Gonatas NK, Silberberg DH. MHC antigen expression on bulk isolated macrophage-microglia from newborn mouse brain: induction of Ia antigen expression by gamma-interferon. *J Neuroimmunol* 1987; **15**: 263–278.

286. Jordan FL, Thomas WE. Identification of microglia in primary cultures of mixed cerebral cortical cells. *Brain Res Bull* 1987; **19**: 153–159.

287. Sutter A, Gerdes C, Jarling E. Microglial contaminants as the source of IL-1 in astrocyte cultures. *Abstract First European Meeting on Glial Cell Function in Health and Disease, Heidelberg* 1994, March 24–27, p. 174.

288. Kim YS, Tauber MG. Neurotoxicity of glia activated by gram-positive bacterial products depends on nitric oxide production. *Infect Immun* 1996; **64**: 3148–3153.

289. Demerle-Pallardy C, Lonchampt M, Chabrier P. Nitric oxide synthase induction in glial cells: effect on neuronal survival. *Life Sci* 1993; **52**: 1883–1890.

290. Zielasek J, Tausch M, Toyka KV, Hartung H. Production of nitrite by

neonatal rat microglial cells/brain macrophages. *Cell Immunol* 1992; **141**: 111–120.

291. Corradin SB, Mauel J, Donini SD, Quattrocchi E, Ricciardi-Castagnoli P. Inducible nitric oxide synthase activity of cloned murine microglial cells. *GLIA* 1993; **7**: 255–262.

292. Zhang X, Morisson DC. Lipopolysaccharide-induced selective priming effects on tumor necrosis factor α and nitric oxide production in mouse peritoneal macrophages. *J Exp Med* 1993; **177**: 511–516.

293. Simmons ML, Murphy S. Induction of nitric oxide in glial cells. *J Neurochem* 1992; **59**: 897–905.

294. Hewett SJ, Corbett JA, McDaniel ML, Choi DW. Interferon-γ and interleukin-1β induce nitric oxide formation from primary mouse astrocytes. *Neurosci Lett* 1993; **164**: 229–232.

295. Galea E, Reis DJ, Fox ES, Xu H, Feinstein DL. CD14 mediates endotoxin induction of nitric oxide synthase in cultured brain glial cells. *J Neuroimmunol* 1996; **64**: 19–28.

296. Simmons ML, Murphy S. Roles for protein kinases in the induction of nitric oxide synthase in astrocytes. *GLIA* 1994; **11**: 227–234.

297. Lee SH, Liu W, Brosnan CF, Dickson DW. Characterization of primary human fetal dissociated central nervous system with an emphasis on microglia. *Lab Invest* 1992; **67**: 465–476.

298. Goureau O, Lepoivre M, Courtois Y. Lipopolysaccharide and cytokines induce a macrophage-type of nitric oxide synthase in bovine retinal pigmented epithelial cells. *Biochem Biophys Res Commun* 1992; **186**: 854–859.

299. Peterson PK, Hu S, Anderson WR, Chao CC. Nitric oxide production and neurotoxicity mediated by activated microglia from human versus mouse brain. *J Infect Dis* 1994; **170**: 457–460.

300. Ruuls SR, Van der Linden S, Sontrop K, Huitinga I, Dijkstra CD. Aggravation of experimental allergic encephalomyelitis by administration of nitric oxide synthase inhibitors. *Clin Exp Immunol* 1996; **103**: 467–476.

301. Ii M, Sunamoto M, Ohnishi K, Ichimori Y. β-amyloid protein-dependent nitric oxide production from microglial cells and neurotoxicity. *Brain Res* 1996; **720**: 93–100.

302. Goodwin JL, Uemura E, Cunnick JE. Microglial release of nitric oxide by the synergistic action of β-amyloid and IFN-gamma. *Brain Res* 1995; **692**: 207–214.

303. Dawson TM, Dawson VL, Snyder SH. A novel neuronal messenger molecule in brain: the free radical, nitric oxide. *Ann Neurol* 1992; **32**: 297–311.

304. Skaper SD, Facci L, Leon A. Inflammatory mediator stimulation of astrocytes and meningeal fibroblasts induces neuronal degeneration via the nitridergic pathway. *J Neurochem* 1995; **64**: 266–276.

305. Chao CC, Molitor TW, Hu S. Neuroprotective role of IL-4 against activated microglia. *J Immunol* 1993; **151**: 1473–1481.

306. Lipton SA. Requirement for macrophages in neuronal injury induced by HIV envelope protein gp120. *NeuroReport* 1992; **3**: 913–915.

307. Bronstein DM, Perez-Otano I, Sun V, Mullis Sawin SB, Chan J, Wu GC, *et al.* Glia-dependent neurotoxicity and neuroprotection in mesencephalic cultures. *Brain Res* 1995; **704**: 112–116.

308. Gelbard HA, Nottet HSLM, Swindells S, Jett M, Dzenko KA, Genis P, *et al.* Platelet-activating factor: a candidate human immunodeficiency virus type 1-induced neurotoxin. *J Virol* 1994; **68**: 4628–4635.

309. Misko TP, Moore WM, Kasten TP, Nickols GA, Corbett JA, Tilton RG, *et al.* Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. *Eur J Pharmacol* 1993; **233**: 119–125.

310. Cross AH, Misko TP, Lin RF, Hickey WF, Trotter JL, Tilton RG. Aminoguanidine, an inhibitor of inducible nitric oxide synthase, ameliorates experimental allergic encephalomyelitis in SJL mice. *J Clin Invest* 1994; **93**: 2684–2690.

311. Romanic AM, Madri JA. Extracellular matrix-degrading proteinases in the nervous system. *Brain Pathol* 1994; **4**: 145–156.

312. Southan GJ, Szabo C. Selective pharmacological inhibition of distinct nitric oxide synthase isoforms. *Biochem Pharmacol* 1997; **51**: 383–394.

313. Park SK, Lin HL, Murphy S. Nitric oxide limits transcriptional induction of nitric oxide synthase in glial cells. *Biochem Biophys Res Commun* 1994; **201**: 762–768.

314. Assreuy J, Cunha FQ, Liew FY, Moncada S. Feedback inhibition of nitric oxide synthase activity by nitric oxide. *Br J Pharmacol* 1993; **108**: 833–837.

315. Feinstein DL, Galea E, Reis DJ. Norepinephrine suppresses inducible nitric oxide synthase activity in rat astroglial cultures. *J Neurochem* 1993; **60**: 1945–1948.

316. Minghetti L, Nicolini A, Polazzi E, Creminon C, Maclouf J, Levi G. Inducible nitric oxide synthase expression in activated rat microglial cultures is downregulated by exogenous prostaglandin E2 and by cyclooxygenase inhibitors. *GLIA* 1997; **19**: 152–160.

317. Hu S, Sheng WS, Peterson PK, Chao CC. Differential regulation by cytokines of production of nitric oxide by human astrocytes. *GLIA* 1995; **15**: 491–494.

318. Park SK, Grzybicki D, Lin HL, Murphy S. Modulation of inducible nitric oxide synthase expression in astroglial cells. *Neuropharmacology* 1994; **33**: 1419–1423.

319. Perretti M, Szabo C, Thiermermann C. Effect of interleukin-4 and

interleukin-10 on leucocyte migration and nitric oxide production in the mouse. *Br J Pharmacol* 1995; **116**: 2251–2257.

320. Liew FY, Ii Y, Severn A, Millott S, Schmidt J, Salter M, *et al.* A possible novel pathway of regulation by murine T helper type-2 (Th2) cells of a Th1 cell activity via the modulation of the induction of nitric oxide synthase on macrophages. *J Immunol* 1991; **21**: 2489–2494.

321. Young MRI, Farietta T, Crayton JW. Production of nitric oxide and transforming growth factor-β in developing and adult rat brain. *Mech Ageing Dev* 1995; **79**: 115–126.

322. Finch CE, Laping NJ, Morgan TE, Nichols NR, Pasinetti GM. TGF-beta 1 is an organizer of responses to neurodegeneration. *J Cell Biochem* 1993; **53**: 14–22.

323. Kiefer R, Streit WJ, Toyka KV, Kreutzberg GW, Hartung H. Transforming growth factor-β1: a lesion-associated cytokine of the nervous system. *Int J Dev Neurosci* 1995; **13**: 331–339.

324. Wahl SM, Allen JB, McCartney-Francis N, Morganti-Kossmann MC, Kossmann T, Ellingsworth L, *et al.* Macrophage- and astrocyte-derived transforming growth factor β as a mediator of central nervous system dysfunction in acquired immune deficiency syndrome. *J Exp Med* 1991; **173**: 981–991.

325. Pasinetti GM, Nichols NR, Tocco G, Morgan T, Laping N, Finch CE. Transforming growth factor β1 and fibronectin messenger RNA in rat brain: responses to injury and cell-type localization. *Neuroscience* 1993; **54**: 893–907.

326. Peress NS, Perillo E, Seidman RJ. Glial transforming growth factor (TGF)-β isotypes in multiple sclerosis: differential glial expression of TGF-β1, 2 and 3 isotypes in multiple sclerosis. *J Neuroimmunol* 1996; **71**: 115–123.

327. Flanders KC, Lippa CF, Smith TW, Pollen DA, Sporn MB. Altered expression of transforming growth factor-β in Alzheimer's disease. *Neurology* 1995; **45**: 1561–1569.

328. Peress NS, Perillo E. Differential expression of TGF-beta 1,2 and 3 isotypes in Alzheimer's disease: a comparative immunohistochemical study with cerebral infarction, aged human and mouse control brains. *J Neuropathol Exp Neurol* 1995; **54**: 802–811.

329. Samuels V, Barrett JM, Bockman S, Pantazis CG, Allen MB Jr. Immunocytochemical study of transforming growth factor expression in benign and malignant gliomas. *Am J Pathol* 1989; **134**: 895–902.

330. Yamada N, Kato M, Yamashita H, Nister M, Miyazono K, Heldin C, *et al.* Enhanced expression of transforming growth factor-β and its type-I and type-II receptors in human glioblastoma. *Int J Cancer* 1995; **62**: 386–392.

331. Cheifetz S, Hernandez H, Leiho M, ten Dijke P, Iwata KK, Massague J. Distinct transforming growth factor-β (TGFβ) receptor subsets as determinants of cellular responsiveness to three TGF-β isoforms. *J Biol Chem* 1990; **265**: 20533–20538.

332. Chao CC, Hu S, Sheng WS, Peterson PK. Tumor necrosis factor-alpha production by human fetal microglial cells: regulation by other cytokines. *Dev Neurosci* 1995; **17**: 97–105.

333. Merrill JE, Zimmerman RP. Natural and induced cytotoxicity of oligodendrocytes by microglia is inhibitable by TGFβ. *GLIA* 1991; **4**: 327–331.

334. Gilbert RS, Herschman HR. Transforming growth factor beta differentially modulates the inducible nitric oxide synthase gene in distinct cell types. *Biochem Biophys Res Commun* 1993; **195**: 380–384.

335. Ding A, Nathan CF, Graycar J, Derynck R, Stuehr DJ, Srimal S. Macrophage deactivating factor and transforming growth factors-β1, -β2, -β3 inhibit induction of macrophage nitrogen oxide synthesis by IFN gamma. *J Immunol* 1990; **145**: 940–944.

336. Wahl SM, Hunt Da, Wakefield LM, McCartney-Francis N, Wahl LM, Roberts AB, *et al.* Transforming growth factor beta (TGF-β) induces monocyte chemotaxis and growth factor production. *Proc Natl Acad Sci USA* 1987; **84**: 5788–5792.

337. Racke MK, Dhib-Jalbut S, Cannella B, Albert PS, Raine CS, McFarlin DE. Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-β1. *J Immunol* 1991; **146**: 3012–3017.

338. Kuruvilla AP, Shah R, Hochwald GM, Liggitt HD, Palladino MA, Thorbecke GJ. Protective effect of transforming growth factor β1 on experimental autoimmune diseases in mice. *Proc Natl Acad Sci USA* 1991; **88**: 2918–2921.

339. Karpus WJ, Swanborg RH. CD4+ suppressor cells inhibit the function of effector cells of experimental autoimmune encephalomyelitis through a mechanism involving transforming growth factor-β. *J Immunol* 1991; **146**: 1163–1168.

340. Johns LD, Sriram S. Experimental allergic encephalomyelitis: neutralizing antibody to TGFβ1 enhances the clinical severity of the disease. *J Neuroimmunol* 1993; **47**: 1–8.

341. Santambrogio L, Hochwald GM, Saxena B, Leu C, Martz JE, Carlino JA, *et al.* Studies on the mechanisms by which tranforming growth factor-β (TGF-β) protects against allergic encephalomyelitis. *J Immunol* 1993; **151**: 1116–1127.

342. Rimaniol A, Lekieffre S, Serrano A, Masson A, Benavides J, Zavala F. Biphasic transforming growth factor-β production flanking the pro-inflammatory cytokine response in cerebral response in cerebral trauma. *NeuroReport* 1995; **7**: 133–136.

343. Issazadeh S, Mustafa M, Ljungdahl A, Hojeberg B, Dagerlind A, Elde R, *et al.* Interferon gamma, interleukin 4 and transforming growth factor β in experimental autoimmune encephalomyelitis in Lewis rats: dynamics of cellular mRNA expression in the central nervous system and lymphoid cells. *J Neurosci Res* 1995; **40**: 579–590.

344. McNeill H, Williams C, Guan J, Dragunow M, Lawlor P, Sirimanne E, *et al.* Neuronal rescue with transforming growth factor-beta 1 after hypoxic-ischaemic brain injury. *NeuroReport* 1994; **5**: 901–904.

345. Lindholm D, Castren E, Kiefer R, Zafra F, Thoenen H. Transforming growth factor-β1 in the rat brain: increase after injury and inhibition of astrocyte proliferation. *J Cell Biol* 1992; **117**: 395–400.

346. Saad B, Constam DB, Ortmann R, Moos M, Fontana A, Schachner M. Astrocyte-derived TGF-β2 and NGF differentially regulate neuronal recognition molecule expression by cultured astrocytes. *J Cell Biol* 1991; **115**: 473–484.

347. Behzadian MA, Wang X, Jiang B, Caldwell RB. Angiostatic role of astrocytes: suppression of vascular endothelial cell growth by TGF-β and other inhibitory factor(s). *GLIA* 1995; **15**: 480–490.

348. Chao CC, Hu S, Sheng WS, Tsang M, Peterson PK. Tumor necrosis factor-alpha mediated the release of bioactive transforming growth factor-beta in murine microglial cell cultures. *Clin Immunol Immunopathol* 1995; **77**: 358–365.

349. da Cunha A, Jefferson JA, Jackson RW, Vitkovic L. Glial cell-specific mechanism of TGF-β1 induction by IL-1 in cerebral cortex. *J Neuroimmunol* 1993; **42**: 71–86.

350. McCartney-Francis N, Mizel D, Wong H, Wahl LM, Wahl SM. TGF-β regulates production of growth factors and TGF-β by human peripheral blood monocytes. *Growth Factors* 1990; **4**: 27–35.

351. Yee JA, Yan L, Dominguez JC, Allan EH, Martin TJ. Plasminogen-dependent activation of latent transforming growth factor β (TGFβ) by growing cultures of osteoblast-like cells. *J Cell Physiol* 1993; **157**: 528–534.

352. Miyazono K, Yuki K, Takaku F, Wernstedt C, Kanzaki T, Olofsson A, *et al.* Latent forms of TGF-β: structure and biology. *Ann NY Acad Sci* 1990; **593**: 51–58.

353. Lyons RM, Gentry LE, Purchio AF, Moses HL. Mechanism of activation of latent recombinant transforming growth factor β1 by plasmin. *J Cell Biol* 1990; **110**: 1361–1367.

354. Sprengers ED, Kluft C. Plasminogen activator inhibitors. *Blood* 1987; **69**: 381–387.

355. Oates JA, Wood AJJ. Tissue plasminogen activator. *New Engl J Med* 1988; **319**: 925–931.

356. Wun T, Reich E. An inhibitor of plasminogen activation from human placenta. *J Biol Chem* 1987; **262**: 3646–3653.

357. Verheijen JH, Chang GTG, Kluft C. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma. *Thromb Haemostas* 1984; **51**: 392–395.

358. Vassalli JD, Sappino A, Belin D. The plasminogen activator/plasmin system. *J Clin Invest* 1991; **88**: 1067–1072.

359. Nakajima K, Takemoto N, Kohsaka S. Retinoic acid enhances the secretion of plasminogen from cultured rat microglia. *FEBS Lett* 1992; **314**: 167–170.

360. Nakajima K, Tsuzaki N, Nagata K, Takemoto N, Kohsaka S. Production and secretion of plasminogen in cultured rat brain microglia. *FEBS Lett* 1992; **308**: 179–182.

361. Nakajima K, Nagata K, Hamanoue M, Takemoto N, Kohsaka S. Microglia-derived elastase produces a low-molecular-weight plasminogen that enhances neurite outgrowth in rat neocortical explant cultures. *J Neurochem* 1993; **61**: 2155–2163.

362. Faber-Elman A, Miskin R, Schwartz M. Components of the plasminogen activator system in astrocytes are modulated by tumor necrosis factor-alpha and interleukin-1β through similar signal transduction pathways. *J Neurochem* 1995; **65**: 1524–1535.

363. Kalderon N, Ahonen K, Fedoroff S. Developmental transition in plasticity properties of differentiating astrocytes: age-related biochemical profile of plasminogen activators in astroglial cultures. *GLIA* 1990; **3**: 413–425.

364. Toshniwal PK, Firestone SL, Barlow GH, Tiku ML. Characterization of astrocyte plasminogen activator. *J Neurol Sci* 1987; **80**: 277–287.

365. Monard D. Cell-derived proteases and protease inhibitors as regulators of neurite outgrowth. *Trends Neurosci* 1988; **11**: 541–544.

366. Seeds NW, Williams BL, Bickford PC. Tissue plasminogen activator induction in Purkinje neurons after cerebellar motor learning. *Science* 1995; **270**: 1992–1994.

367. Tsirka SE, Rogove AD, Strickland S. Neuronal cell death and tPA. *Nature* 1996; **384**: 123–124.

368. Akenami FOT, Koskiniemi M, Farkkila M, Vaheri A. Cerebrospinal fluid plasminogen activator inhibitor-1 in patients with neurological disease. *J Clin Pathol* 1997; **50**: 157–160.

369. Akenami FOT, Siren V, Koskiniemi M, Siimes MA, Vaheri A. Cerebrospinal fluid activity of tissue plasminogen activator in patients with neurological diseases. *J Clin Pathol* 1996; **49**: 577–580.

370. Cuzner ML, Gveric D, Strand C, Loughlin AJ, Paemen L, Opdenakker G, *et al.* The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. *J Neuropathol Exp Neurol* 1996; **55**: 1194–1204.

371. Banati RB, Graeber MB. Surveillance, intervention and cytotoxicity: is there a protective role of microglia? *Dev Neurosci* 1994; **16**: 114–127.

372. Berdeaux A. Nitric oxide: an ubiquitous messenger. *Fundam Clin Pharmacol* 1993; **7**: 401–411.